<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Chandrajit P Raut, MD, MSc, FACS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anette Duensing, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vicki L Keedy, MD, MSCI
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth K Tanabe, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert Maki, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alberto S Pappo, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 11, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gastrointestinal stromal tumors (GISTs) are rare mesenchymal neoplasms of the gastrointestinal tract. GISTs that arise from the bowel wall typically present as subepithelial neoplasms in the stomach and small intestine; however, they can also arise in any portion of the gastrointestinal tract and, occasionally, the omentum, mesentery, and peritoneum [
         <a href="#rid1">
          1-5
         </a>
         ]. Most GISTs harbor characteristic mutations in
         <em>
          KIT
         </em>
         or platelet-derived growth factor receptor alpha (
         <em>
          PDGFRA)
         </em>
         , while mutations in succinate dehydrogenase (
         <em>
          SDH
         </em>
         ) or other genes are less frequent.
        </p>
        <p>
         The clinical presentation, diagnosis, and prognosis of GISTs will be discussed here. The approach to treatment for localized  (
         <a class="graphic graphic_algorithm graphicRef139723" href="/z/d/graphic/139723.html" rel="external">
          algorithm 1
         </a>
         ) and advanced GISTs  (
         <a class="graphic graphic_algorithm graphicRef127116" href="/z/d/graphic/127116.html" rel="external">
          algorithm 2
         </a>
         ) is discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7727.html" rel="external">
          "Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7730.html" rel="external">
          "Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7725.html" rel="external">
          "Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         GISTs are rare neoplasms that represent approximately 1 to 2 percent of primary gastrointestinal (GI) cancers [
         <a href="#rid2">
          2,3,6
         </a>
         ]. Despite their rarity, GISTs are the most common mesenchymal (ie, nonepithelial) neoplasms of the GI tract [
         <a href="#rid2">
          2,3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2689168574">
         <span class="h2">
          Age of presentation
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adults
         </strong>
         – GISTs occur predominantly in older adults, with a median age of diagnosis between 65 and 69 years [
         <a href="#rid7">
          7-11
         </a>
         ]. GISTs rarely occur in those under the age of 40 years [
         <a href="#rid7">
          7
         </a>
         ]. However, the age of diagnosis can range between 10 and 100 years old.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pediatric patients
         </strong>
         – Approximately 0.4 to 2 percent of GISTs arise in children and young adults under the age of 20 years [
         <a href="#rid12">
          12
         </a>
         ]. Among pediatric patients with GIST, the median age at diagnosis is 15 years [
         <a href="#rid12">
          12-15
         </a>
         ]. These patients typically have an underlying genetic predisposition to these neoplasms [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="local">
          'Genetic syndromes'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H103772297">
         <span class="h2">
          Geographic incidence
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of GISTs varies according to geographic location. In a systematic review of 29 studies conducted in 19 countries, the most commonly reported incidence rates were between 10 and 15 cases per million population per year [
         <a href="#rid7">
          7
         </a>
         ]. The highest incidence rates were seen in China (Hong Kong and Shanghai), Taiwan, Korea, and Norway (19 to 22 cases per million population per year), whereas the lowest incidence rates were seen in the Shanxi province of China (4.3 cases per million population per year) as well as the Czech Republic and Slovakia (5.2 cases per million population per year). In the United States and Canada, the incidence of GISTs ranges between approximately 7 to 8 cases per million population per year [
         <a href="#rid7">
          7,8,16-18
         </a>
         ].
        </p>
        <p>
         It is important to note that the incidence of GISTs also depends upon the availability of accurate pathologic diagnostic criteria and is subject to selection bias. As an example, in one Surveillance, Epidemiology, and End Results (SEER) analysis of 6142 cases identified using a GIST-specific histology code, the incidence of GISTs rose between 2001 and 2011 from 5.5 to 7.8 cases per million population per year [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         In addition, most GISTs are diagnosed incidentally, so the true incidence of this disease may be difficult to determine accurately. While some autopsy data suggest that gastric GISTs are more common than previously estimated (with tumors &lt;1 cm identified in up to 35 percent cases) [
         <a href="#rid19">
          19,20
         </a>
         ], other data suggest that only a few microscopic tumors grow to a clinically relevant size with malignant potential, which is consistent with the relatively low annual incidence rate of this disease [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H319079837">
         <span class="h2">
          Sex
         </span>
         <span class="headingEndMark">
          —
         </span>
         GISTs are equally common in male and female patients (1:1 ratio) [
         <a href="#rid7">
          7
         </a>
         ]. However, succinate dehydrogenase (
         <em>
          SDH)
         </em>
         deficient tumors, most frequently seen in pediatric patients, are twice as common in females than males [
         <a href="#rid21">
          21,22
         </a>
         ]. (See
         <a class="local">
          'SDH-deficient tumors'
         </a>
         below and
         <a class="local">
          'GIST syndromes in pediatric and AYA patients'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3781659499">
         <span class="h2">
          Ethnicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States, GISTs are more common among African Americans compared with other ethnicities [
         <a href="#rid16">
          16,23
         </a>
         ]. In a SEER database analysis of 7204 patients with GISTs diagnosed between 2002 and 2015, African Americans had the highest overall incidence rate (13.7 cases per million population), followed by Asians/Pacific Islanders (11 cases per million population), White Americans (6.5 cases per million population), and American Indians/Alaskan Natives (2.8 cases per million population) [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4010996876">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         GISTs represent a distinct entity from other mesenchymal tumors of the gastrointestinal (GI) tract [
         <a href="#rid24">
          24
         </a>
         ]. GISTs were initially thought to be derived from smooth muscle, based upon histologic assessment. However, their immunohistochemistry profile differs from that of leiomyomas and leiomyosarcomas arising from other sites (eg, uterus or soft tissues). GISTs have near-universal expression of the CD117 antigen  (
         <a class="graphic graphic_table graphicRef79128" href="/z/d/graphic/79128.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid25">
          25
         </a>
         ], whereas true leiomyosarcomas, leiomyomas, and other spindle cell tumors of the gastrointestinal tract are typically CD117 negative. The CD117 antigen is synonymous with the transmembrane KIT receptor tyrosine kinase, which is the product of the
         <em>
          KIT
         </em>
         proto-oncogene (ie,
         <em>
          c-KIT
         </em>
         ; the human homolog of the viral oncogene
         <em>
          v-KIT
         </em>
         [
         <a href="#rid26">
          26
         </a>
         ]). Approximately 80 percent of GISTs carry a mutation in the
         <em>
          KIT
         </em>
         gene, leading to a structural variant of the KIT protein that is abnormally activated and enables oncogenic signaling in the cell [
         <a href="#rid25">
          25,27-29
         </a>
         ]. (See
         <a class="local">
          'Molecular alterations'
         </a>
         below.)
        </p>
        <p>
         GISTs likely originate from the interstitial cells of Cajal (ICCs), sometimes referred to as the GI pacemaker cells. ICCs are located in the intramuscular layer of the bowel wall below the epithelium; they regulate peristalsis by forming the interface between the autonomic innervation of the bowel wall and the smooth muscle itself [
         <a href="#rid30">
          30
         </a>
         ]. GISTs arising in the GI tract typically present as subepithelial masses, which is generally consistent with the primary location of the ICCs. (See
         <a class="medical medical_review" href="/z/d/html/2666.html" rel="external">
          "Endoscopic ultrasound for the characterization of subepithelial lesions of the upper gastrointestinal tract", section on 'Gastrointestinal stromal tumors'
         </a>
         .)
        </p>
        <p>
         ICCs have the immunophenotypic and ultrastructural features of both smooth muscle and neuronal differentiation. It is assumed that GISTs originate from CD34-positive ICC stem cells within the wall of the GI tract and differentiate toward the pacemaker cell phenotype [
         <a href="#rid31">
          31-33
         </a>
         ]. Therefore, a link between GISTs and ICCs has been proposed because both cell types can express KIT protein and CD34 [
         <a href="#rid34">
          34
         </a>
         ]. An exception is the extremely rare "extragastrointestinal stromal tumor" (EGIST), a primary GIST that arises outside of the GI tract. EGISTs are phenotypically identical to true GIST lesions of GI tract origin [
         <a href="#rid4">
          4,35,36
         </a>
         ]. While this finding seemingly contradicts the hypothesis of GISTs arising from ICCs within the gut wall [
         <a href="#rid32">
          32,37
         </a>
         ], it is thought that these tumors arise from ICCs that were accidentally dispersed during embryogenesis.
        </p>
        <p>
         In support of the origin of GISTs from ICCs, resected tumors have been accompanied by diffuse ICC hyperplasia in the adjacent GI tract wall (Auerbach plexus) in several kindreds with primary familial GIST [
         <a href="#rid21">
          21,37-40
         </a>
         ]. These are thought to represent precursor lesions to GIST in these patients. Diffuse ICC hyperplasia may also represent a precursor lesion to sporadic GIST [
         <a href="#rid20">
          20
         </a>
         ]. In these cases, they must be distinguished from syndromic ICC hyperplasia seen in hereditary syndromes characterized by the development of GISTs [
         <a href="#rid41">
          41
         </a>
         ]. (See
         <a class="local">
          'Genetic syndromes'
         </a>
         below.)
        </p>
        <p>
         Various studies have elucidated the genetic events responsible for the transformation of microscopic GIST lesions (ie, those &lt;1 cm in diameter) into clinically relevant GISTs. For example, homozygous inactivation of the basic helix-loop-helix leucine zipper (bHLHZ) transcription factor MYC-associated factor X (MAX) leads to p16 inactivation and cell cycle perturbation [
         <a href="#rid42">
          42
         </a>
         ]. The presence of MAX inactivation in both microscopic GISTs/low-risk GISTs and metastases from the same patient indicates that it is likely an early step in GIST progression. Furthermore, inactivation of dystrophin (DMD, chromosome Xp21.1), which was present in more than 90 percent of metastatic GISTs in one study, is likely a late event in GIST progression [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3435538837">
         <span class="h1">
          GENETIC SYNDROMES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although a majority of GISTs are sporadic, approximately 5 percent of patients with GISTs have one of several genetic syndromes associated with the development of these tumors. These genetic syndromes include primary familial GIST syndrome, neurofibromatosis type 1 (NF1), Carney-Stratakis syndrome, and Carney triad. Familial cases of GIST are indistinguishable from sporadic cases in terms of phenotype, histology, and molecular features. [
         <a href="#rid44">
          44,45
         </a>
         ]. Patients diagnosed with GISTs who also present with clinical characteristics consistent with these syndromes should be referred for genetic counseling and appropriate germline testing. (See
         <a class="medical medical_review" href="/z/d/html/103304.html" rel="external">
          "Genetic counseling: Family history interpretation and risk assessment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H468716942">
         <span class="h2">
          Primary familial GIST syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with primary familial gastrointestinal stromal tumor (GIST) syndrome have tumors characterized by heritable mutations in either the
         <em>
          KIT
         </em>
         or platelet-derived growth factor receptor alpha (
         <em>
          PDGFRA
         </em>
         ) genes [
         <a href="#rid46">
          46-54
         </a>
         ]. These families have a predisposition to the early development of GISTs in multiple primary sites, such as the stomach and small intestine. In addition, patients with germline
         <em>
          KIT
         </em>
         mutations sometimes present with skin hyperpigmentation, dysphagia, or gastrointestinal (GI) autonomic nerve tumors, such as paragangliomas [
         <a href="#rid46">
          46-50
         </a>
         ]. By contrast, patients with germline
         <em>
          PDGFRA
         </em>
         mutations often present with intestinal fibromatosis and inflammatory fibroid polyps, a diagnosis formerly classified as intestinal neurofibromatosis/neurofibromatosis 3b (INF/NF3b) [
         <a href="#rid52">
          52-54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1080177146">
         <span class="h2">
          Neurofibromatosis type 1
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with NF1 have a high incidence of GISTs, which occur most frequently in the small intestine (&gt;70 percent) [
         <a href="#rid44">
          44,55
         </a>
         ]. GISTs associated with NF1 are often multifocal, have spindled histology, and have low mitotic rates. Somatic mutations in the
         <em>
          KIT
         </em>
         or
         <em>
          PDGFRA
         </em>
         genes are rare among these tumors, in contrast with sporadic cases of GISTs [
         <a href="#rid44">
          44,45
         </a>
         ]. Nevertheless, KIT is often expressed in these
         <em>
          KIT
         </em>
         /
         <em>
          PDGFRA
         </em>
         wild-type tumors, but the mechanism of overexpression is not clear. Further details on the clinical features and diagnosis of NF1 are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">
          "Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis", section on 'Soft tissue sarcomas'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1013925">
         <span class="h2">
          GIST syndromes in pediatric and AYA patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Carney-Stratakis syndrome and Carney triad are syndromes commonly associated with the development of GISTs in pediatric, adolescent and young adult (AYA) patients [
         <a href="#rid56">
          56
         </a>
         ]. These syndromes are typically characterized by succinate dehydrogenase (
         <em>
          SDH
         </em>
         ) deficient tumors. Approximately 85 percent of pediatric and AYA patients with GIST lack oncogenic mutations in
         <em>
          KIT
         </em>
         and
         <em>
          PDGFRA
         </em>
         , and a majority of these are characterized by molecular alterations in the
         <em>
          SDH
         </em>
         family of genes. (See
         <a class="local">
          'KIT/PDGFRA wild-type GISTs'
         </a>
         below and
         <a class="local">
          'SDH-deficient tumors'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2648314060">
         <span class="h3">
          Carney-Stratakis syndrome (dyad)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Carney-Stratakis syndrome, also referred to as Carney-Stratakis dyad, is an autosomal dominant disorder with incomplete penetrance that is typically diagnosed in children and young adults at a median age of 19 to 21 years [
         <a href="#rid57">
          57
         </a>
         ]. Patients with this rare, heritable condition present with the dyad of GISTs and paragangliomas. (See
         <a class="medical medical_review" href="/z/d/html/5231.html" rel="external">
          "Paragangliomas: Epidemiology, clinical presentation, diagnosis, and histology", section on 'Carney-Stratakis dyad'
         </a>
         .)
        </p>
        <p>
         GISTs in patients with Carney-Stratakis syndrome are not commonly associated with mutations in
         <em>
          KIT
         </em>
         or
         <em>
          PDGFRA
         </em>
         [
         <a href="#rid58">
          58
         </a>
         ]. Rather, in many cases, they are associated with germline mutations in the
         <em>
          SDH
         </em>
         gene, which cause loss of function of an SDH family enzyme (typically SDHB, SDHC, or SDHD) [
         <a href="#rid59">
          59-61
         </a>
         ]. Patients with GIST who are suspected of having Carney-Stratakis syndrome should undergo genetic testing for germline abnormalities in the
         <em>
          SDH
         </em>
         gene [
         <a href="#rid62">
          62-64
         </a>
         ]. Further details on
         <em>
          SDH
         </em>
         -deficient GISTs are discussed below. (See
         <a class="local">
          'SDH-deficient tumors'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2461443142">
         <span class="h3">
          Carney triad
         </span>
         <span class="headingEndMark">
          —
         </span>
         Carney triad is an extremely rare syndrome consisting of GIST, paraganglioma, and pulmonary chondromas [
         <a href="#rid65">
          65
         </a>
         ]. It predominantly affects young women and is generally considered to be a nonhereditary disorder caused by hypermethylation of the SDHC promoter. This results in epigenetic inactivation of the
         <em>
          SDHC
         </em>
         gene locus with functional impairment of the SDH complex [
         <a href="#rid57">
          57,65-68
         </a>
         ]. However, almost 10 percent of patients harbor germline variants in
         <em>
          SDHA
         </em>
         ,
         <em>
          SDHB
         </em>
         , or
         <em>
          SDHD
         </em>
         , suggesting that there might be a hereditary contribution to Carney triad in some cases [
         <a href="#rid69">
          69
         </a>
         ]. (See
         <a class="local">
          'KIT/PDGFRA wild-type GISTs'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5231.html" rel="external">
          "Paragangliomas: Epidemiology, clinical presentation, diagnosis, and histology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7727.html" rel="external">
          "Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3181606872">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
        </p>
        <p class="headingAnchor" id="H4131106889">
         <span class="h2">
          Location
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary tumor
         </strong>
         – GISTs occur throughout the gastrointestinal (GI) tract from the esophagus to the anus. Within the GI tract, primary tumor sites are most common in the stomach (40 to 60 percent) and jejunum/ileum (25 to 30 percent) [
         <a href="#rid16">
          16,70-72
         </a>
         ]. Less common sites include the esophagus (≤1 percent), duodenum (5 percent), colorectum (5 to 15 percent), and anus (&lt;0.5 percent) [
         <a href="#rid73">
          73
         </a>
         ]. Extragastrointestinal stromal tumors (EGISTs) are rare tumors (&lt;5 percent) that lack any association with the bowel wall and occur in the retroperitoneum, mesentery, and omentum [
         <a href="#rid4">
          4,12,36,72
         </a>
         ]; however, these could also be metastases from an undetected primary tumor.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The presentation of GISTs varies depending on the primary tumor location [
         <a href="#rid74">
          74
         </a>
         ]. For example, GISTs involving the upper GI tract (eg, stomach, small intestine, or esophagus) could present with GI bleeding, dysphagia, or obstructive jaundice, whereas those involving the colon or rectum could present with constipation, bowel obstruction, or urinary hesitancy in men (due to a rectal tumor abutting the prostate [
         <a href="#rid75">
          75
         </a>
         ]). (See
         <a class="medical medical_review" href="/z/d/html/7727.html" rel="external">
          "Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract", section on 'Presentation and management at specific sites'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Metastatic disease
         </strong>
         – Approximately 10 to 20 percent of patients present with metastatic disease. Patients with multifocal disease are usually classified as advanced (metastatic) stage, although some (particularly those with rare hereditary conditions) are affected by multiple primaries [
         <a href="#rid76">
          76
         </a>
         ]. (See
         <a class="local">
          'Primary familial GIST syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The most common sites of metastases are the liver, omentum, and peritoneum, and these could present with abdominal pain or bowel obstruction. GISTs rarely metastasize to abdominal lymph nodes (except in pediatric patients) or outside the abdominal cavity. Pulmonary metastases are also uncommon with GISTs, unlike most soft tissue sarcomas. (See
         <a class="local">
          'Evaluation for metastatic disease'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/14259.html" rel="external">
          "Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma", section on 'Clinical presentation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3724700274">
         <span class="h2">
          Presenting symptoms by age
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adult patients with GISTs typically have a different clinical presentation compared with pediatric patients, which is discussed below. (See
         <a class="local">
          'Pediatric and AYA patients'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1044631926">
         <span class="h3">
          Adults
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adult patients with GISTs commonly present with the following symptoms [
         <a href="#rid10">
          10,12,77-79
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Overt or occult GI bleeding – 28 percent (small intestine) and 50 percent (gastric)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Incidental finding (asymptomatic) – 13 to 25 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abdominal pain/discomfort – 8 to 17 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute abdomen – 2 to 14 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Asymptomatic abdominal mass – 5 percent
        </p>
        <p>
        </p>
        <p>
         Patients with GISTs can present with a wide range of symptoms. Most patients with subepithelial masses are asymptomatic, and their tumors are often discovered incidentally. For example, GISTs can be detected during an endoscopic study; elective surgical procedures (eg, sleeve gastrectomy for patients with obesity [
         <a href="#rid80">
          80
         </a>
         ]); or on imaging done for another purpose. Other patients with indolent endoluminal progression of the primary tumor may present with nonspecific chronic symptoms (eg, early satiety or bloating). (See
         <a class="medical medical_review" href="/z/d/html/2666.html" rel="external">
          "Endoscopic ultrasound for the characterization of subepithelial lesions of the upper gastrointestinal tract", section on 'Gastrointestinal stromal tumors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/88536.html" rel="external">
          "Bariatric procedures for the management of severe obesity: Descriptions", section on 'Sleeve gastrectomy'
         </a>
         .)
        </p>
        <p>
         However, some tumors may eventually grow large enough to ulcerate or cause pain [
         <a href="#rid81">
          81,82
         </a>
         ]. In certain circumstances, such patients may present with symptoms that require urgent clinical evaluation such as tumor rupture, GI bleeding, bowel perforation, or GI obstruction [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2547.html" rel="external">
          "Approach to acute lower gastrointestinal bleeding in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2548.html" rel="external">
          "Approach to acute upper gastrointestinal bleeding in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15075.html" rel="external">
          "Overview of gastrointestinal tract perforation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8037.html" rel="external">
          "Etiologies, clinical manifestations, and diagnosis of mechanical small bowel obstruction in adults"
         </a>
         .)
        </p>
        <p>
         Paraneoplastic syndromes are rare in adult patients with GISTs; however, potential paraneoplastic syndromes have been reported in a few patients, including non-islet cell tumor hypoglycemia and consumptive hypothyroidism [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Consumptive hypothyroidism
         </strong>
         – In treatment-naïve patients with GIST, consumptive hypothyroidism occurs due to excessive degradation of thyroid hormone caused by overexpression of the thyroid hormone inactivating enzyme type 3 iodothyronine deiodinase (D3) within large GISTs. (See
         <a class="medical medical_review" href="/z/d/html/7886.html" rel="external">
          "Disorders that cause hypothyroidism", section on 'Consumptive hypothyroidism'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">
          "Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Thyroid dysfunction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with GIST who present with this condition typically require high levels of thyroid hormone supplementation. Consumptive hypothyroidism is not considered a treatment-related toxicity related to tyrosine kinase inhibitors (TKIs); nevertheless, patients with consumptive hypothyroidism who initiate TKI therapy need close monitoring of thyroid function, with adjustment of thyroid supplementation as needed. Referral to an endocrinologist is indicated in patients with consumptive hypothyroidism who are severely symptomatic and/or are having difficulty managing thyroid supplementation. Further details on the management of consumptive hypothyroidism are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7725.html" rel="external">
          "Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors", section on 'Side effects and management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">
          "Treatment of primary hypothyroidism in adults", section on 'Persistent elevation in TSH'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3070746049">
         <span class="h3">
          Pediatric and AYA patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pediatric and adolescent and young adult (AYA) patients have a different clinical presentation compared with adults. In these patients, the most common presenting symptoms and signs are GI bleeding, fatigue, and anemia. These patients also have a more indolent disease course, despite the higher propensity for multifocal gastric tumors and lymph node metastases, disease recurrence, and metastatic disease [
         <a href="#rid84">
          84-86
         </a>
         ]. (See
         <a class="local">
          'Other risk factors'
         </a>
         below.)
        </p>
        <p>
         Additionally, patients with the Carney-Stratakis dyad or Carney triad can present with paragangliomas and their associated symptoms, such as catecholamine secretion or mass effect. Further details on the clinical presentation of paragangliomas are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5231.html" rel="external">
          "Paragangliomas: Epidemiology, clinical presentation, diagnosis, and histology"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1902169753">
         <span class="h2">
          Physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         In all patients with suspected GISTs, the physical examination should include a detailed abdominal examination. GISTs may present as palpable abdominal masses either due to the primary tumor or intra-abdominal metastases (eg, liver, omentum, or peritoneum). Signs of acute abdomen or peritonitis may indicate the presence of GI bleeding, tumor rupture, bowel perforation, or GI obstruction. However, most patients with localized GISTs may have no specific physical exam findings, as some tumors present without symptoms, and extra-abdominal metastases are rare. (See
         <a class="medical medical_review" href="/z/d/html/6862.html" rel="external">
          "Evaluation of the adult with abdominal pain", section on 'Diagnostic approach to acute abdominal pain'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3093654606">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         GISTs are detected either incidentally in asymptomatic patients, or during the evaluation of the symptomatic patient. As such, the diagnostic evaluation in patients with GISTs often requires attention to specific clinical findings as well as a high level of suspicion for the disease. Both imaging and endoscopic procedures are necessary to the initial diagnostic evaluation of GISTs.
        </p>
        <p class="headingAnchor" id="H4264168317">
         <span class="h2">
          Imaging the primary tumor
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with suspected GIST, we suggest imaging using computed tomography (CT) for initial evaluation of the primary tumor. Magnetic resonance imaging (MRI) is a reasonable alternative in patients who cannot receive CT contrast or have a rectal primary. We typically do not choose positron emission tomography (PET) scanning using fluorodeoxyglucose (FDG-PET) in combination with CT (PET-CT) to evaluate the primary tumor because it is not sufficiently specific to make a preoperative diagnosis.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CT
         </strong>
         – Contrast-enhanced CT of the abdomen and pelvis is the imaging method of choice to characterize an abdominal mass suspicious for GIST. Oral as well as intravenous contrast should be administered to define the bowel margins. The usual CT appearance of a GIST is that of a solid, smoothly contoured mass that enhances brightly with intravenous contrast. Very large tumors (&gt;15 cm) may appear more complex due to necrosis, hemorrhage, or degenerating components  (
         <a class="graphic graphic_diagnosticimage graphicRef113958" href="/z/d/graphic/113958.html" rel="external">
          image 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         CT imaging can also assess for the extent of the primary mass, including local invasion into adjacent structures. However, it may be difficult to identify the primary location of a large mass on CT because of exophytic growth. CT also can better visualize small intestinal thickness and the presence of bowel perforation when compared with MRI [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MRI
         </strong>
         – Although CT remains the preferred initial diagnostic imaging study for the evaluation of a suspected GIST, MRI of the abdomen and pelvis has a comparable diagnostic yield compared with CT and lacks radiation exposure [
         <a href="#rid88">
          88
         </a>
         ]. MRI may also be offered as an alternative to CT in patients who cannot receive intravenous CT contrast. (See
         <a class="medical medical_review" href="/z/d/html/14613.html" rel="external">
          "Radiation-related risks of imaging"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         MRI may also be preferred over CT to evaluate primary rectal GISTs or those undergoing preoperative evaluation. Small GISTs on MRI appear round and symmetric, whereas larger GISTs are asymmetric and lobulated [
         <a href="#rid74">
          74
         </a>
         ]. (See
         <a class="local">
          'Rectal EUS versus MRI'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          PET-CT
         </strong>
         – PET-CT has not replaced CT or MRI as the initial imaging modality of choice in patients suspected of having a GIST. PET-CT imaging is highly sensitive for detecting tumors with a high glucose metabolism, including GISTs [
         <a href="#rid89">
          89
         </a>
         ]; however, it is not sufficiently specific to make a preoperative diagnosis.
        </p>
        <p>
        </p>
        <p>
         The approach to imaging metastatic disease in patients with a confirmed diagnosis of GIST is discussed below. (See
         <a class="local">
          'Evaluation for metastatic disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2240970677">
         <span class="h2">
          Diagnostic procedures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Procedures that lead to the diagnosis of GIST are chosen based on the sites of primary and metastatic disease.
        </p>
        <p class="headingAnchor" id="H3390746627">
         <span class="h3">
          Upper endoscopy with EUS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Upper endoscopy with endoscopic ultrasound (EUS) is the preferred diagnostic procedure to further characterize upper gastrointestinal (GI) tumors suspicious for GIST involving the stomach, small intestine, or esophagus. GISTs present with characteristic findings on both endoscopy and EUS. (See
         <a class="medical medical_review" href="/z/d/html/2666.html" rel="external">
          "Endoscopic ultrasound for the characterization of subepithelial lesions of the upper gastrointestinal tract", section on 'Gastrointestinal stromal tumors'
         </a>
         .)
        </p>
        <p>
         On endoscopy, both GISTs and leiomyomas may appear as a submucosal mass with smooth margins, with a normal overlying mucosa, and bulging into the gastric lumen. Central ulceration is occasionally seen  (
         <a class="graphic graphic_picture graphicRef52275" href="/z/d/graphic/52275.html" rel="external">
          picture 1
         </a>
         ).
        </p>
        <p>
         The addition of EUS to endoscopy can distinguish intramural from extramural tumors by identifying the layer of origin. On EUS, GISTs are typically hypoechoic, homogeneous lesions with well-defined margins, although they can rarely have irregular margins and ulcerations. Most GISTs originate from within the muscularis propria (fourth layer of the GI tract); small lesions may originate from the muscularis mucosa (second layer). Infrequently, the tumors are inhomogeneous, which has been attributed to liquefaction necrosis, connective tissue, and cystic and hyaline degeneration. Further details on the endosonographic findings of GISTs are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2666.html" rel="external">
          "Endoscopic ultrasound for the characterization of subepithelial lesions of the upper gastrointestinal tract", section on 'Endosonographic findings in GISTs'
         </a>
         .)
        </p>
        <p>
         Furthermore, EUS enables guided-tissue acquisition for diagnostic studies, including immunohistochemistry (IHC), which is discussed below. (See
         <a class="local">
          'Indications for preoperative biopsy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3434455455">
         <span class="h3">
          Colonoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Colonoscopy is used to identify masses suspicious for GIST that present in the colon, rectum, and anus. Colorectal GISTs are extremely rare and comprise approximately 0.1 percent of all colorectal tumors [
         <a href="#rid90">
          90
         </a>
         ]. Small colonic polypoid masses can be resected endoscopically. However, masses that are larger or subepithelial are more challenging to biopsy using endoscopy alone, as this approach could result in inadequate tissue sampling for a definitive diagnosis, bleeding, and/or seeding of the biopsy tract with tumor. Therefore, these masses should either be surgically resected or (in the case of rectal GISTs) sampled using EUS-guided biopsy. (See
         <a class="local">
          'Rectal EUS versus MRI'
         </a>
         below and
         <a class="local">
          'Indications for surgical resection'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3144909178">
         <span class="h3">
          Rectal EUS versus MRI
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both rectal endoscopic ultrasound (EUS) and/or magnetic resonance imaging (MRI) may play a role in the diagnostic evaluation of suspected rectal GISTs. A similar imaging approach may also be used for patients with extremely rare anal GISTs.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rectal EUS
         </strong>
         – Rectal EUS may be useful to help delineate anatomy prior to EUS-guided fine needle aspiration (EUS-FNA) of rectal GISTs. However, because rectal GISTs often lack nodal involvement, it does not have as much utility in the nodal staging of these tumors as in rectal adenocarcinomas. (See
         <a class="medical medical_review" href="/z/d/html/2674.html" rel="external">
          "Endoscopic ultrasound for evaluating patients with rectal cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MRI
         </strong>
         – MRI of the abdomen and pelvis may be offered to patients with rectal GISTs in order to delineate the anatomic extent of disease prior to surgery. Characteristic MRI findings of rectal GISTs include low to intermediate signal intensity on T1-weighted images and a heterogeneous or homogeneous high signal intensity on T2-weighted images [
         <a href="#rid91">
          91
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5309.html" rel="external">
          "Principles of magnetic resonance imaging"
         </a>
         and
         <a class="local">
          'Indications for surgical resection'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4277804038">
         <span class="h2">
          Tissue sampling
         </span>
        </p>
        <p class="headingAnchor" id="H365495135">
         <span class="h3">
          Indications for preoperative biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The preoperative diagnosis of GISTs requires a high degree of suspicion and familiarity with its radiologic or endoscopic appearance. For patients with large, locally advanced lesions suspected to be GIST, we suggest preoperative biopsy rather than initial surgical resection to confirm the diagnosis, especially for patients with metastatic disease or those eligible for neoadjuvant
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/7730.html" rel="external">
          "Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Neoadjuvant therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H897718102">
         <span class="h3">
          Approaches to biopsy
         </span>
        </p>
        <p class="headingAnchor" id="H1987128739">
         <span class="h4">
          EUS-guided biopsy (primary tumor)
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients undergoing preoperative biopsy of the primary tumor, we suggest endoscopic ultrasound (EUS)-guided tissue sampling rather than endoscopic sampling alone or percutaneous biopsy [
         <a href="#rid92">
          92
         </a>
         ]. Tissue acquisition can be performed using either EUS-FNA or EUS-guided fine needle biopsy (EUS-FNB). (See
         <a class="medical medical_review" href="/z/d/html/2656.html" rel="external">
          "Endoscopic ultrasound-guided fine needle aspiration in the gastrointestinal tract"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2649.html" rel="external">
          "Endoscopic ultrasound-guided fine needle biopsy in the gastrointestinal tract"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          EUS-guided fine needle aspiration
         </strong>
         – The diagnosis of most GIST tumors may be obtained using EUS-FNA, along with the combined use of cytologic analysis, IHC for KIT protein expression, and genetic analysis for characteristic GIST mutations. In one study of 65 patients undergoing EUS-FNA for an upper gastrointestinal tract submucosal lesion, among the 28 lesions with a definitive pathologic diagnosis, the sensitivity for diagnosis of GIST was 82 percent and the specificity was 100 percent [
         <a href="#rid93">
          93
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2656.html" rel="external">
          "Endoscopic ultrasound-guided fine needle aspiration in the gastrointestinal tract", section on 'Upper GI tract lesions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          EUS-guided fine needle biopsy
         </strong>
         – Endoscopic biopsies alone using standard techniques usually do not obtain sufficient tissue for a definite diagnosis of GIST [
         <a href="#rid94">
          94
         </a>
         ]. While EUS-FNB forceps also may not yield enough tissue, their main utility is to exclude other lesions that arise submucosally. Snare biopsies (in which a polypectomy snare is used to remove a large piece of tissue) can result in perforation of GISTs and generally should be avoided, except in carefully selected cases [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H467872597">
         <span class="h4">
          Percutaneous biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who are unable to undergo successful EUS-guided biopsy of the primary tumor, image-guided percutaneous biopsy is an alternative option to sample either the primary tumor or distant metastatic sites. However, percutaneous biopsy is less-preferred due to the potential risk of primary tumor rupture or spread of metastatic disease. Such patients may also be evaluated for surgical resection. (See
         <a class="local">
          'Indications for surgical resection'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Percutaneous biopsy of the primary tumor
         </strong>
         – Image-guided percutaneous biopsy of the primary tumor carries the theoretical risk of rupture of the tumor capsule with peritoneal spread of disease. However, there is no evidence in patients receiving
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         that individuals undergoing a percutaneous biopsy have inferior outcomes compared with those who do not [
         <a href="#rid95">
          95
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7725.html" rel="external">
          "Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7730.html" rel="external">
          "Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Percutaneous biopsy of metastatic disease
         </strong>
         – Image guided percutaneous biopsy may be used to biopsy distant sites of metastatic disease, such as the liver, omentum, or peritoneum. This approach may be used in patients whose primary site has been biopsied via alternative approaches (such as EUS-guided biopsy) and the pathologic diagnosis of GIST still remains in question (eg, due to inadequate tissue sampling) or if the metastatic site is more accessible for biopsy than the primary tumor site. The most common modalities include CT- or ultrasound-guided biopsy. Image guided percutaneous biopsies should be performed at institutions that specialize in such procedures, given the theoretical risk of peritoneal spread of disease or biopsy tract seeding with this procedure (See
         <a class="medical medical_review" href="/z/d/html/3587.html" rel="external">
          "Approach to liver biopsy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2210449466">
         <span class="h3">
          Indications for surgical resection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical resection of the primary tumor is indicated for disease that cannot be safely biopsied, or when initial biopsy attempts have been either unsuccessful or non-diagnostic. Patients with unresectable or metastatic disease may also undergo surgical resection of a symptomatic primary tumor if it requires immediate surgical intervention (eg, due to hemorrhage, tumor rupture, bowel obstruction, or gastrointestinal perforation). (See
         <a class="local">
          'Evaluation for metastatic disease'
         </a>
         below.)
        </p>
        <p>
         The approach to surgical resection of GISTs based on primary tumor site is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7727.html" rel="external">
          "Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract", section on 'Presentation and management at specific sites'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1018423636">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of GISTs is established using histopathology, immunohistochemistry (IHC), and identification of disease-specific mutations characteristic to these neoplasms.
        </p>
        <p class="headingAnchor" id="H1178773848">
         <span class="h2">
          Histopathology
         </span>
        </p>
        <p class="headingAnchor" id="H3652845303">
         <span class="h3">
          Cellular morphology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The cellular morphology of GISTs ranges from predominantly spindle shaped to epithelioid in character. Histologically, the appearance of these tumors usually falls into one of three relatively uniform categories:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Spindle cell type – 70 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Epithelioid type – 20 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mixed type – 10 percent
        </p>
        <p>
        </p>
        <p>
         GISTs of the spindle cell type are composed of relatively uniform eosinophilic cells arranged in short fascicles or whorls  (
         <a class="graphic graphic_picture graphicRef114562" href="/z/d/graphic/114562.html" rel="external">
          picture 2
         </a>
         ) [
         <a href="#rid30">
          30
         </a>
         ]. Compared with leiomyomas, the eosinophilic cytoplasm is paler and often has a fibrillary appearance. The nuclei tend to be uniform, and there may be juxtanuclear cytoplasmic vacuoles and nuclear palisading. Stromal collagen is minimal in most cases, and stromal hemorrhage is a common feature. Marked cytologic pleomorphism is rare and should raise the possibility of an alternative diagnosis if present.
        </p>
        <p>
         GISTs of the epithelioid type are composed of rounded cells with variably eosinophilic or clear cytoplasm  (
         <a class="graphic graphic_picture graphicRef114562" href="/z/d/graphic/114562.html" rel="external">
          picture 2
         </a>
         ) [
         <a href="#rid34">
          34
         </a>
         ]. They tend to have round to oval nuclei with vesicular chromatin, and the architecture may be nested, potentially leading to confusion with an epithelial or melanocytic neoplasm. Interestingly, epithelioid type GISTs are more often KIT-expression negative, harbor platelet-derived growth factor receptor alpha (
         <em>
          PDGFRA
         </em>
         ) mutations, and are present most often in the stomach [
         <a href="#rid5">
          5
         </a>
         ]. Epithelioid GISTs are also more common in pediatric than in adult patients [
         <a href="#rid88">
          88,96
         </a>
         ].
        </p>
        <p>
         GISTs of the mixed type may have areas of abrupt transition between spindle and epithelioid areas or complex intermingling of both cell types throughout  (
         <a class="graphic graphic_picture graphicRef114563" href="/z/d/graphic/114563.html" rel="external">
          picture 3
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1408804082">
         <span class="h3">
          Immunohistochemistry
         </span>
         <span class="headingEndMark">
          —
         </span>
         IHC staining can help to distinguish GISTs from other subepithelial tumors that may arise in the gastrointestinal tract  (
         <a class="graphic graphic_table graphicRef79128" href="/z/d/graphic/79128.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          KIT (CD117)
         </strong>
         – The most prominent diagnostic marker of GIST is the near universal overexpression of the receptor tyrosine kinase KIT (CD117), which is easily identified by positive IHC staining  (
         <a class="graphic graphic_picture graphicRef114564" href="/z/d/graphic/114564.html" rel="external">
          picture 4
         </a>
         ). However, the relationship between expression of the KIT protein (CD117) and the
         <em>
          KIT
         </em>
         mutation in GISTs is not entirely straightforward. (See
         <a class="local">
          'KIT mutations'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Approximately 95 percent of GISTs are positive for KIT expression on IHC, and a majority are due to known
         <em>
          KIT
         </em>
         mutations. However, some GISTs that express KIT are
         <em>
          KIT
         </em>
         mutation negative. Overexpression of KIT and presumably aberrant KIT signaling may be present even in the absence of
         <em>
          KIT
         </em>
         mutations, especially in pediatric GISTs and GISTs that arise in the setting of neurofibromatosis type 1 (NF1) [
         <a href="#rid21">
          21,39,44,45,97
         </a>
         ]. These tumors typically stain on IHC for KIT but are
         <em>
          KIT
         </em>
         wild-type (ie, have no detectable mutations in the
         <em>
          KIT
         </em>
         gene), and they have a poor response to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         [
         <a href="#rid45">
          45
         </a>
         ]. In tumors deficient of succinate dehydrogenase (
         <em>
          SDH
         </em>
         ) without an identifiable
         <em>
          KIT
         </em>
         mutation, there is evidence that the mechanism of KIT overexpression is related to epigenetic changes near the
         <em>
          KIT
         </em>
         oncogene [
         <a href="#rid98">
          98
         </a>
         ]. (See
         <a class="local">
          'KIT/PDGFRA wild-type GISTs'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         GISTs that are negative for KIT expression on IHC account for 4 to 5 percent of cases. Within this small subset tumors, many also lack
         <em>
          KIT
         </em>
         mutations, and some instead harbor activating mutations in the
         <em>
          PDGFRA
         </em>
         gene [
         <a href="#rid99">
          99,100
         </a>
         ]. By contrast, in some GISTs that do not express KIT on IHC,
         <em>
          KIT
         </em>
         gene mutations have been detected, suggesting that transcriptional silencing has occurred via a different mechanism [
         <a href="#rid101">
          101
         </a>
         ]. This phenomenon also tends to occur as part of a resistance mechanism during
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         therapy [
         <a href="#rid102">
          102
         </a>
         ]. In such patients and in those with an unclear diagnosis, mutational analysis is necessary to confirm the diagnosis of GIST. (See
         <a class="local">
          'Molecular alterations'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          DOG-1 and PKC-theta
         </strong>
         – DOG-1 (discovered on GIST-1) and PKC-theta (protein kinase C theta) are two immunohistochemical markers that are positive in GIST irrespective of
         <em>
          KIT
         </em>
         or
         <em>
          PDGFRA
         </em>
         mutational status. DOG-1 especially has become a widely used diagnostic marker in addition to KIT IHC [
         <a href="#rid102">
          102-107
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other markers
         </strong>
         – Between 60 to 70 percent of GISTs are positive for
         <strong>
          CD34
         </strong>
         ; 30 to 40 percent for
         <strong>
          smooth muscle actin
         </strong>
         ; 5 percent for
         <strong>
          S-100 protein
         </strong>
         ; and 1 to 2 percent for
         <strong>
          desmin or keratin
         </strong>
         [
         <a href="#rid1">
          1,25,108
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Molecular alterations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Molecular alterations that are commonly identified in GISTs include mutations in
         <em>
          KIT
         </em>
         ,
         <em>
          PDGFRA
         </em>
         , and the family of
         <em>
          SDH
         </em>
         genes. Other molecular aberrations can be present but are much less common. (See
         <a class="local">
          'Other mutations'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H534783062">
         <span class="h3">
          Approach to testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Concurrent with initiation of first-line therapy with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , an assessment of
         <em>
          KIT/PDGFRA
         </em>
         tumor mutational status using DNA sequencing techniques is advised during the initial evaluation of most patients diagnosed with GIST because clinical responses to systemic therapy (eg, imatinib and other tyrosine kinase inhibitors) correlate with tumor genotype. The approach to molecular testing varies based on institutional practices and available techniques (eg, next-generation sequencing [NGS] versus assessment of individual mutations) [
         <a href="#rid109">
          109
         </a>
         ]. If pursued, at minimum, molecular testing should assess for
         <em>
          KIT
         </em>
         mutations. If no
         <em>
          KIT
         </em>
         mutation is detected, reflex testing can be obtained for
         <em>
          PDGFRA
         </em>
         mutations. If the tumor is negative for both
         <em>
          KIT
         </em>
         and
         <em>
          PDGFRA
         </em>
         mutations, extended panel testing can be sent to assess for less common mutations. SDH-deficient tumors are typically diagnosed based on expert pathology review of tumor morphology and immunohistochemistry. (See
         <a class="local">
          'KIT/PDGFRA wild-type GISTs'
         </a>
         below.)
        </p>
        <p>
         However, molecular analysis is not required as part of initial assessment for all patients. We often do not obtain mutational testing in patients with smaller GISTs (eg, 0.5 mm to 2 cm) and low mitotic rate who undergo complete resection; these patients are typically observed and mutational testing does not alter management. (See
         <a class="medical medical_review" href="/z/d/html/7725.html" rel="external">
          "Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors"
         </a>
         .)
        </p>
        <p>
         Similarly, some UpToDate contributors do not obtain further molecular testing for patients receiving neoadjuvant
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         whose tumor histology and immunohistochemistry are consistent with either a
         <em>
          KIT
         </em>
         or
         <em>
          PDGFRA
         </em>
         mutation. For those with insufficient tissue samples for molecular testing, repeat biopsy is not required if patients are responding to imatinib. (See
         <a class="medical medical_review" href="/z/d/html/7730.html" rel="external">
          "Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Neoadjuvant therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3110914841">
         <span class="h3">
          KIT mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 95 percent of GISTs in adults overexpress the tyrosine kinase receptor KIT. Approximately 80 percent of GISTs have
         <em>
          KIT
         </em>
         gene mutations that lead to constitutive activation of the KIT receptor [
         <a href="#rid2">
          2,25,27,28,101,110,111
         </a>
         ]. These gain-of-function mutations in
         <em>
          KIT
         </em>
         are observed in both sporadic and hereditary cases. (See
         <a class="local">
          'Immunohistochemistry'
         </a>
         above.)
        </p>
        <p>
         The
         <em>
          KIT
         </em>
         proto-oncogene has been postulated to play an important role in tumorigenesis [
         <a href="#rid2">
          2,25,27,28,37,46,101,110,111
         </a>
         ]. In normal cells, KIT receptor tyrosine kinase activity is regulated by binding of the endogenous ligand for the receptor (known as KIT ligand or stem cell factor [SCF]) [
         <a href="#rid38">
          38
         </a>
         ].
         <em>
          KIT
         </em>
         mutations, however, lead to a ligand-independent activation of KIT; this results in constitutive activation of downstream signaling pathways that stimulate cell survival, growth, and proliferation  (
         <a class="graphic graphic_figure graphicRef113954" href="/z/d/graphic/113954.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid112">
          112
         </a>
         ].
         <em>
          KIT
         </em>
         mutations in GIST can occur in different exons of the gene and can be either point mutations, deletions, or insertions. There is no single mutational hotspot, although some regions are affected more often than others.
        </p>
        <p>
         Primary
         <em>
          KIT
         </em>
         mutations in GISTs most commonly occur in exons 11 and 9 and more rarely in exons 13, 17, 14, and 18  (
         <a class="graphic graphic_figure graphicRef113953" href="/z/d/graphic/113953.html" rel="external">
          figure 2
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exon 11
         </strong>
         – Exon 11 is the most common
         <em>
          KIT
         </em>
         mutation and occurs in approximately 70 percent of newly diagnosed GISTs [
         <a href="#rid25">
          25,112
         </a>
         ]. This mutation codes for the intracellular juxtamembrane domain of the receptor. This region usually has an autoinhibitory function on kinase activation, which is alleviated by the mutation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exon 9
         </strong>
         – Exon 9
         <em>
          KIT
         </em>
         mutations are detected in 12 to 15 percent of cases. This mutation affects the extracellular dimerization domain and allows receptor dimerization in the absence of ligand and subsequent kinase activation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other
         </strong>
         <strong>
          <em>
           KIT
          </em>
         </strong>
         <strong>
          mutations
         </strong>
         –
         <em>
          KIT
         </em>
         mutations in exons 13, 14, 17, and 18 are rare and occur in approximately 1 to 2 percent of cases [
         <a href="#rid113">
          113
         </a>
         ]. These mutations affect the kinase domain (exon 13 and 14 mutations alter ATP-binding; exon 17 and 18 mutations alter the activation loop) [
         <a href="#rid112">
          112
         </a>
         ]. While uncommon in newly diagnosed GISTs, they are seen at a high frequency as secondary mutations in GISTs that develop
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         resistance [
         <a href="#rid112">
          112
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7725.html" rel="external">
          "Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          KIT wild-type
         </strong>
         – Approximately 15 percent of GISTs lack mutations in the
         <em>
          KIT
         </em>
         gene (ie, are
         <em>
          KIT
         </em>
         wild-type). The pathogenesis of these subsets is discussed below. (See
         <a class="local">
          'PDGFRA mutations'
         </a>
         below and
         <a class="local">
          'KIT/PDGFRA wild-type GISTs'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          PDGFRA mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         A subset of GISTs lacking
         <em>
          KIT
         </em>
         mutations have activating mutations in the tyrosine kinase platelet-derived growth factor receptor alpha (
         <em>
          PDGFRA
         </em>
         ) gene [
         <a href="#rid5">
          5,99,100,114
         </a>
         ].
         <em>
          KIT
         </em>
         and
         <em>
          PDGFRA
         </em>
         are mutually exclusive oncogenic mutations in GISTs. Moreover,
         <em>
          PDGFRA
         </em>
         mutations are more likely to occur in GISTs that lack IHC expression of KIT. Patients with
         <em>
          PDGFRA
         </em>
         mutations have tumors that most commonly arise in the stomach and present with more indolent disease [
         <a href="#rid115">
          115,116
         </a>
         ]. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
         The frequency of
         <em>
          PDGFRA
         </em>
         mutations among patients with GIST ranges between 2 and 14 percent [
         <a href="#rid117">
          117
         </a>
         ]. In one analysis,
         <em>
          PDGFRA
         </em>
         mutations was detected in approximately 7 percent of tumors (80 of 1105 GIST samples), although the study was enriched by a large number of tumors that were negative for KIT (CD117) expression on IHC [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
         Various molecular alterations in the
         <em>
          PDGFRA
         </em>
         pathway exist, including [
         <a href="#rid5">
          5,40
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exon 18
         </strong>
         – Exon 18 is the most common
         <em>
          PDGFRA
         </em>
         mutation and accounts for approximately 80 to 90 percent of PDGFRA mutations. This mutation affects the activation loop in the second tyrosine kinase domain.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          D842V
         </strong>
         – D842V exon 18 mutations occur in approximately 62 percent of
         <em>
          PDGFR
         </em>
         A mutations. This mutant isoform confers significant resistance to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         [
         <a href="#rid40">
          40,99,100
         </a>
         ] and requires the use of alternative tyrosine kinase inhibitors such as
         <a class="drug drug_general" data-topicid="126556" href="/z/d/drug information/126556.html" rel="external">
          avapritinib
         </a>
         and
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          ripretinib
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/7725.html" rel="external">
          "Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors", section on 'Avapritinib for PDGFRA D842V mutant tumors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7725.html" rel="external">
          "Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors", section on 'Ripretinib'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Non-D842V
         </strong>
         – Non-D842V exon 18 mutations occur in approximately 27 percent of
         <em>
          PDGFRA
         </em>
         mutations. In general, non-D842V mutations in exon 18 confer sensitivity to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exon 12
         </strong>
         – Exon 12 makes up approximately 9 percent of
         <em>
          PDGFRA
         </em>
         mutations and affects the juxtamembrane domain of the receptor.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other mutations
         </strong>
         –
         <em>
          PDGFRA
         </em>
         mutations in other exons such as those in exons 14 and 10 are relatively rare.
        </p>
        <p>
        </p>
        <p>
         The influence of
         <em>
          PDGFRA
         </em>
         mutational status in the adjuvant setting, neoadjuvant setting, and as initial therapy in patients with metastatic disease is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7730.html" rel="external">
          "Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Molecular subtypes and primary resistance'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7730.html" rel="external">
          "Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Role of genotyping'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7725.html" rel="external">
          "Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors", section on 'PDGFRA mutations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3194789498">
         <span class="h3">
          KIT/PDGFRA wild-type GISTs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with
         <em>
          KIT/PDGFRA
         </em>
         wild-type GISTs (ie, tumors without detectable mutations in
         <em>
          KIT
         </em>
         or
         <em>
          PDGFRA
         </em>
         ) comprise approximately 10 to 15 percent of all GIST cases.
         <em>
          KIT/PDGFRA
         </em>
         wild-type GISTs are seen in patients with syndromes such as Carney-Stratakis syndrome (
         <em>
          SDH
         </em>
         gene mutations), Carney triad (epigenetic changes affecting the succinate dehydrogenase C [SDHC] promoter), and those with NF1 (
         <em>
          NF1
         </em>
         gene mutation) [
         <a href="#rid118">
          118
         </a>
         ]. (See
         <a class="local">
          'Genetic syndromes'
         </a>
         above.)
        </p>
        <p>
         One series examined the various molecular subtypes of
         <em>
          KIT
         </em>
         /
         <em>
          PDGFRA
         </em>
         wild-type GISTs in 95 patients who presented with either a GIST at age &lt;19 or a wild-type GIST at age ≥19. Among the 84 patients with adequate tissue for analysis, three molecular subtypes were defined [
         <a href="#rid14">
          14
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          SDHX
         </em>
         mutations – 66 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         SDHC promoter hypermethylation – 22 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         SDH competent – 12 percent (which included mutations in
         <em>
          NF1
         </em>
         ;
         <em>
          BRAF
         </em>
         V600E; other rare mutations or fusions; or no identified abnormalities)
        </p>
        <p>
        </p>
        <p>
         <em>
          KIT
         </em>
         /
         <em>
          PDGFRA
         </em>
         wild-type GISTs are often localized to the stomach, multicentric in origin, and can have an indolent clinical course [
         <a href="#rid56">
          56,84
         </a>
         ]. Many of these tumors arise in younger patients. Approximately 85 percent of all GISTs diagnosed in children and adolescents are
         <em>
          KIT/PDGFRA
         </em>
         wild-type. Furthermore, many are also associated with mutations and/or functional loss of expression of an SDH enzyme. Nevertheless, these
         <em>
          KIT/PDGFRA
         </em>
         wild-type GISTs can occasionally occur in adults, with virtually identical features to those observed in pediatric patients [
         <a href="#rid119">
          119
         </a>
         ]. (See
         <a class="local">
          'GIST syndromes in pediatric and AYA patients'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H573700652">
         <span class="h4">
          SDH-deficient tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         SDH-deficient tumors lack mutations in
         <em>
          KIT
         </em>
         or
         <em>
          PDGFRA
         </em>
         [
         <a href="#rid56">
          56
         </a>
         ]. These tumors have loss of function of a succinate dehydrogenase (SDH) family enzyme (SDHA, SDHB, SDHC, or SDHD; commonly combined under the term "SDHx"). This loss of function occurs either due to a mutation in one of the
         <em>
          SDHx
         </em>
         genes or due to epigenetic silencing [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
         Tumor immunostaining for SDHB is appropriate to diagnose SDH deficiency in
         <em>
          KIT/PDGFRA
         </em>
         wild-type GISTs, as absence of SDHB indicates deficiency of any of the
         <em>
          SDHx
         </em>
         genes
         <em>
          .
         </em>
         Patients with such tumors should be referred for evaluation of genetic syndromes such as Carney-Stratakis syndrome. (See
         <a class="local">
          'Carney-Stratakis syndrome (dyad)'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5231.html" rel="external">
          "Paragangliomas: Epidemiology, clinical presentation, diagnosis, and histology", section on 'Carney-Stratakis dyad'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5850.html" rel="external">
          "Pheochromocytoma and paraganglioma in children"
         </a>
         .)
        </p>
        <p>
         <em>
          KIT
         </em>
         /
         <em>
          PDGFRA
         </em>
         mutation-negative GISTs are poorly responsive to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         . The approach to systemic therapy in patients with
         <em>
          KIT
         </em>
         /
         <em>
          PDGFRA
         </em>
         wild-type GISTs is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7730.html" rel="external">
          "Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Molecular subtypes and primary resistance'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7725.html" rel="external">
          "Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors", section on 'SDH-deficient tumors and those associated with NF1'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1304431448">
         <span class="h4">
          Other mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of
         <em>
          KIT
         </em>
         /
         <em>
          PDGFRA
         </em>
         wild-type GISTs harbor other genetic abnormalities that are mutually exclusive with
         <em>
          KIT
         </em>
         and
         <em>
          PDGFRA
         </em>
         mutations. Some of these molecular alterations can be targeted with available systemic therapies and may have important therapeutic implications in GISTs. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          BRAF
         </strong>
         – Mutations in
         <em>
          BRAF
         </em>
         V600E can be detected in up to 13 percent of patients with
         <em>
          KIT
         </em>
         /
         <em>
          PDGFRA
         </em>
         wild-type GISTs [
         <a href="#rid120">
          120,121
         </a>
         ], and these tumors may be amenable to treatment with BRAF plus MEK inhibitors [
         <a href="#rid122">
          122
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15408.html" rel="external">
          "Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          NF-1
         </strong>
         – Neurofibromatosis type 1 (NF1)-associated GISTs exhibit increased signaling through the mitogen-activated protein kinase (MAPK) signaling cascade [
         <a href="#rid123">
          123
         </a>
         ], raising the possibility of treatment with MEK inhibitors. (See
         <a class="medical medical_review" href="/z/d/html/90123.html" rel="external">
          "Neurofibromatosis type 1 (NF1): Management and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          NTRK
         </strong>
         – Gene fusions involving neurotrophic tyrosine kinase receptor type 3 (NTRK3) or fibroblast growth factor receptor 1 (FGFR1) have been identified in patients with
         <em>
          KIT
         </em>
         /
         <em>
          PDGFRA
         </em>
         wild-type GISTs. However, other studies suggest that mesenchymal tumors with
         <em>
          NTRK
         </em>
         gene fusions may represent other sarcomas and not GISTs, so this association is controversial [
         <a href="#rid124">
          124
         </a>
         ]. Tumors with these molecular alterations may be targetable with TRK or FGFR inhibitors, respectively [
         <a href="#rid125">
          125
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/122713.html" rel="external">
          "TRK fusion-positive cancers and TRK inhibitor therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4175440379">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of a subepithelial tumor arising in the gastrointestinal (GI) tract includes both benign and malignant tumors, many of which present similarly to GISTs. The distinction between these tumors and GISTs is based upon immunohistochemistry  (
         <a class="graphic graphic_table graphicRef79128" href="/z/d/graphic/79128.html" rel="external">
          table 1
         </a>
         ) and molecular alterations specific to GISTs [
         <a href="#rid37">
          37
         </a>
         ]. (See
         <a class="local">
          'Immunohistochemistry'
         </a>
         above and
         <a class="local">
          'Molecular alterations'
         </a>
         above.)
        </p>
        <p>
         Benign tumors include leiomyoma, schwannoma, and desmoid tumors, and their clinical presentation is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7727.html" rel="external">
          "Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract", section on 'GIST and leiomyoma'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15269.html" rel="external">
          "Peripheral nerve tumors", section on 'Schwannoma'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7746.html" rel="external">
          "Desmoid tumors: Epidemiology, molecular pathogenesis, clinical presentation, diagnosis, and local therapy", section on 'Clinical presentation and diagnosis'
         </a>
         .)
        </p>
        <p>
         Malignant tumors include leiomyosarcoma, malignant melanoma, malignant peripheral nerve sheath tumor, inflammatory myofibroblastic tumor, and metaplastic ("sarcomatoid") carcinoma [
         <a href="#rid126">
          126
         </a>
         ]. The clinical presentation of these tumors is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7727.html" rel="external">
          "Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract", section on 'Leiomyosarcoma'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/85841.html" rel="external">
          "Overview of the management of advanced cutaneous melanoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15269.html" rel="external">
          "Peripheral nerve tumors", section on 'Malignant peripheral nerve sheath tumors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/114329.html" rel="external">
          "Uncommon sarcoma subtypes", section on 'Inflammatory myofibroblastic tumor'
         </a>
         .)
        </p>
        <p>
         By light microscopy alone, the distinction among GISTs and other tumors (particularly GI tract leiomyomas, leiomyosarcomas, and schwannomas) can be difficult because the histologic findings seen on hematoxylin and eosin (H&amp;E)-stained sections do not reliably or specifically relate to the immunophenotype or the molecular genetics of the lesions [
         <a href="#rid126">
          126
         </a>
         ]. Further details on the histopathology of these tumors are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7727.html" rel="external">
          "Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract", section on 'GIST and leiomyoma'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7727.html" rel="external">
          "Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract", section on 'Leiomyosarcoma'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16350.html" rel="external">
          "Schwannomatoses related to genetic variants other than
          <i>
           NF2
          </i>
          ", section on 'Tumor pathology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1155647299">
         <span class="h1">
          EVALUATION FOR METASTATIC DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         For all patients with a confirmed diagnosis of GIST, we evaluate for metastatic disease using computed tomography (CT) and/or magnetic resonance imaging (MRI) of the abdomen and pelvis, if not already performed during initial diagnostic evaluation. CT can more accurately detect the presence of metastatic disease involving the mesentery, omentum, and peritoneal cavity. However, hepatic metastases may be better visualized by either positron emission tomography (PET)-CT or MRI with gadolinium enhancement, since liver metastases may be isodense on contrast-enhanced CT [
         <a href="#rid127">
          127
         </a>
         ].
        </p>
        <p>
         For primary tumors ≥2 cm in size, we obtain either a chest radiograph or CT of the chest to assess for pulmonary metastases, a rare clinical finding in patients with GIST. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
         PET using fluorodeoxyglucose (FDG-PET) in combination with CT (PET-CT) may have a role in the evaluation of metastatic disease. Baseline PET-CT imaging may be obtained prior to initial therapy with a tyrosine kinase inhibitor in order to assess treatment response in the neoadjuvant or metastatic setting. (See
         <a class="medical medical_review" href="/z/d/html/7725.html" rel="external">
          "Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors", section on 'Assessing response to therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7730.html" rel="external">
          "Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Response assessment'
         </a>
         .)
        </p>
        <p>
         PET-CT imaging can be useful for detecting an unknown primary site or resolving ambiguities from CT (eg, when initial CT findings are inconclusive or inconsistent with the clinical findings) [
         <a href="#rid128">
          128
         </a>
         ]. PET-CT imaging may also be useful in detecting hepatic metastases that may appear isodense on contrast-enhanced CT. The reported sensitivity of PET-CT for GISTs (including metastatic lesions) is 86 to 100 percent [
         <a href="#rid89">
          89,129,130
         </a>
         ]. However, nearly all the data obtained by PET-CT imaging can be found in a good quality CT scan with intravenous contrast, with superior anatomic definition.
        </p>
        <p class="headingAnchor" id="H1685629368">
         <span class="h1">
          STAGING SYSTEM
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with a confirmed diagnosis of GIST are staged using the eighth edition (2017) American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) tumor, node, metastasis (TNM) staging system  (
         <a class="graphic graphic_table graphicRef110847" href="/z/d/graphic/110847.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid131">
          131
         </a>
         ]. In the AJCC staging system, all primary tumor sites follow the same tumor (T) and node (N) designations. However, gastric and omental primaries are staged separately from small intestine, esophageal, colorectal, mesenteric and peritoneal primaries.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          RISK STRATIFICATION AND PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although GISTs can exhibit variable biologic disease behavior, all have the potential to develop into metastatic disease. Based on available clinical risk factors, prognostic models have been developed to predict the relative risks of recurrence and metastasis [
         <a href="#rid108">
          108,132,133
         </a>
         ]. Some of these models can identify patients at risk for recurrence and individualize management with systemic therapy using tyrosine kinase inhibitors (TKIs). (See
         <a class="local">
          'Prognostic and risk stratification models'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2877803080">
         <span class="h2">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Risk factors that influence prognosis in patients with GIST are mainly based on the characteristics of the primary tumor. The most clinically relevant risk factors are as follows:
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Tumor size and mitotic rate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tumor size and mitotic rate are both independent prognostic factors and are used in models to predict aggressive tumor behavior  (
         <a class="graphic graphic_table graphicRef139776" href="/z/d/graphic/139776.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef60930" href="/z/d/graphic/60930.html" rel="external">
          table 4
         </a>
         ). These factors (along with primary tumor site) were identified using data from three large retrospective studies from the Armed Forces Institute of Pathology (AFIP) on GISTs diagnosed and treated largely prior to the era of TKIs [
         <a href="#rid71">
          71,81,82
         </a>
         ]. However, it is not clear how the presence or absence of gene mutations influences these prognostic factors, particularly as the role of targeted treatments specific to tumor mutation status evolves.
        </p>
        <p class="headingAnchor" id="H1995843880">
         <span class="h3">
          Primary tumor site
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, primary tumors arising from the stomach are associated with more favorable survival outcomes compared with those arising from the small intestine, colon, rectum, or mesentery [
         <a href="#rid132">
          132
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastric and small intestinal primaries
         </strong>
         – The prognosis of primary tumors arising from the stomach or small intestine is influenced by size and mitotic count. Based on data from the AFIP series, small tumors with a low mitotic rate have a similarly good prognosis regardless of whether the primary site is gastric or small intestine, with only 2 to 3 percent of such tumors progressing to metastatic disease [
         <a href="#rid81">
          81,82
         </a>
         ]. Large tumors with a high mitotic rate have a similarly poor prognosis, regardless of the primary site, with more than 86 percent of such tumors progressing to metastatic disease. However, intermediate tumors (larger tumors with a low mitotic rate or smaller tumors with a high mitotic rate) arising from the stomach have a more favorable prognosis (metastatic rate of 11 to 15 percent) compared with those arising from the small intestine (metastatic rate &gt;50 percent) [
         <a href="#rid81">
          81,82
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other primary site
         </strong>
         – Patients with colorectal GISTs appear to have similar or slightly decreased relapse-free survival compared with those with small intestinal GISTs. Similarly, patients with GISTs outside the gastrointestinal (GI) tract appear to relapse more frequently [
         <a href="#rid15">
          15,134
         </a>
         ]. However, the effect of primary location on prognosis is more difficult to determine, given the rarity of these tumors.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3904302561">
         <span class="h3">
          Other risk factors
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tumor rupture
         </strong>
         – Tumor rupture (either spontaneously or at surgery) is an independent risk factor that negatively impacts disease-free survival [
         <a href="#rid135">
          135-138
         </a>
         ]. Tumor rupture is included as a prognostic variable in a modified version of the National Institutes of Health consensus criteria for risk stratification (in addition to tumor size, site, and mitotic rate)  (
         <a class="graphic graphic_table graphicRef85938" href="/z/d/graphic/85938.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid138">
          138
         </a>
         ]. However, tumor rupture is not included in the tumor, node, metastasis (TNM) staging system of the American Joint Committee on Cancer (AJCC). (See
         <a class="local">
          'Staging system'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging characteristics
         </strong>
         – Tumor characteristics on computed tomography (CT) or endoscopic ultrasound (EUS) may not only suggest the diagnosis of a GIST but may also correlate with recurrence risk. In general, tumors with higher metastatic potential include those larger than 5 cm; those that are lobulated or enhance heterogeneously; those with mesenteric fat infiltration, ulceration, or regional lymphadenopathy; or those with an exophytic growth pattern on CT [
         <a href="#rid139">
          139-143
         </a>
         ]. By contrast, GISTs with less metastatic potential tend to enhance in a homogeneous pattern and often show an endoluminal growth pattern.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lymph node involvement
         </strong>
         – Data are limited for the prognostic impact of lymph node involvement, given the rarity of this finding in adults with GISTs. As examples, in the data from the AFIP series of gastric and small intestinal GISTs, no patients with nodal involvement were identified [
         <a href="#rid81">
          81,82
         </a>
         ]. In another study from the SEER database analysis of 5138 adults with GISTs, nodal involvement was identified in approximately 5 percent of cases and was associated with decreased cancer-specific and overall survival [
         <a href="#rid144">
          144
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, nodal involvement is common in patients with succinate dehydrogenase (
         <em>
          SDH
         </em>
         )-mutant or
         <em>
          SDH
         </em>
         -epimutant GISTs (65 and 38 percent, respectively) [
         <a href="#rid14">
          14
         </a>
         ]. Such patients with nodal involvement (who tend to be children or young adults) demonstrate more indolent disease and a better prognosis, compared with adults with nodal involvement. (See
         <a class="local">
          'Pediatric and AYA patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Molecular alterations
         </strong>
         – There are limited data for risk assessment based on molecular alterations associated with GISTs. Some studies obtained prior to the modern era of TKI therapy suggest that patients with
         <em>
          KIT
         </em>
         mutations have a worse prognosis than those without
         <em>
          KIT
         </em>
         mutations) [
         <a href="#rid28">
          28,101,114,115,138,145,146
         </a>
         ]. Specific
         <em>
          KIT
         </em>
         mutations are associated with an aggressive phenotype, including those affecting exon 9 [
         <a href="#rid138">
          138,145,147,148
         </a>
         ] and deletions involving codons 557 to 558 on exon 11 [
         <a href="#rid101">
          101,114,115,145,149,150
         </a>
         ]. (See
         <a class="local">
          'Molecular alterations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, it is not clear how the presence or absence of
         <em>
          KIT
         </em>
         gene mutations influences prognosis, particularly as the role of targeted treatments specific to tumor mutation status evolves. (See
         <a class="medical medical_review" href="/z/d/html/7725.html" rel="external">
          "Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors", section on 'Influence of mutations on response to therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3254074805">
         <span class="h2">
          Prognostic and risk stratification models
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based on the risk factors described above, various prognostic models and risk stratification schemes have been proposed to better delineate the prognosis of patients with GISTs. Molecular alterations (eg,
         <em>
          KIT
         </em>
         , platelet-derived growth factor receptor alpha [
         <em>
          PDGFRA
         </em>
         ], or
         <em>
          SDH
         </em>
         mutation status) are not incorporated in these prognostic models, and their prognostic role remains to be defined.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          AFIP prognostic model
         </strong>
         – The prognostic model proposed by the Armed Forces Institute of Pathology (AFIP)  (
         <a class="graphic graphic_table graphicRef139776" href="/z/d/graphic/139776.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef60930" href="/z/d/graphic/60930.html" rel="external">
          table 4
         </a>
         ) is the most commonly used risk stratification scheme in the United States, although others are also available. The AFIP prognostic model is influenced by tumor size, mitotic rate, primary site [
         <a href="#rid82">
          82,151,152
         </a>
         ], and the completeness of resection [
         <a href="#rid70">
          70,153-158
         </a>
         ]. This model was developed by comparing outcomes for different primary sites with long-term follow-up largely prior to the era of TKIs, including 1055 gastric, 629 jejunal/ileal, 144 duodenal, and 111 rectal GISTs [
         <a href="#rid132">
          132
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          NIH risk stratification scheme
         </strong>
         – A modified National Institutes of Health (NIH) risk stratification scheme was developed based on tumor size, mitotic counts, and the addition of tumor rupture  (
         <a class="graphic graphic_table graphicRef85938" href="/z/d/graphic/85938.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid15">
          15
         </a>
         ]. This model proved better than conventional models at predicting 10-year risk for GIST recurrence and are particularly useful for discussing individual risk with patients as they are graphic and easy to explain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          AJCC staging
         </strong>
         – The American Joint Committee on Cancer (AJCC; eighth edition 2017) described rates of disease progression for gastric  (
         <a class="graphic graphic_table graphicRef110724" href="/z/d/graphic/110724.html" rel="external">
          table 6
         </a>
         ), small intestinal  (
         <a class="graphic graphic_table graphicRef110723" href="/z/d/graphic/110723.html" rel="external">
          table 7
         </a>
         ), and rectal GISTs  (
         <a class="graphic graphic_table graphicRef110725" href="/z/d/graphic/110725.html" rel="external">
          table 8
         </a>
         ), stratified by eighth edition (2017) TNM stage at diagnosis  (
         <a class="graphic graphic_table graphicRef110847" href="/z/d/graphic/110847.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid132">
          132
         </a>
         ]. (See
         <a class="local">
          'Staging system'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Memorial Sloan Kettering nomogram
         </strong>
         – The risk of disease recurrence has been quantified through the use of an online
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.mskcc.org%2Fcancer-care%2Ftypes%2Fgastrointestinal-neuroendocrine%2Fprediction-tools&amp;token=6n2wxxPhuxYw98HABYFTuEgqWhwTu2A35tch%2FnAzrZakbptoGocwfvydM%2F5pv5aHc%2FKZuLKwaOLJRmK8D2vfullnfFE7Q7%2Bea5OzaUKxgac%3D&amp;TOPIC_ID=7745" target="_blank">
          GIST nomogram
         </a>
         from Memorial Sloan Kettering Cancer Center that predicts postoperative recurrence-free survival based on primary tumor size, disease site, and mitotic rate [
         <a href="#rid159">
          159-161
         </a>
         ]. This nomogram may be used as an alternative to risk classification systems that stratify patients into discrete categories.
        </p>
        <p>
        </p>
        <p>
         The implications of these prognostic models and risk stratification schemes in selecting patients for adjuvant
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         based upon estimated recurrence risk are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7730.html" rel="external">
          "Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Estimation of recurrence risk'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H369191692">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/120170.html" rel="external">
          "Society guideline links: Gastrointestinal stromal tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6104799">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/17046.html" rel="external">
          "Patient education: Soft tissue sarcoma (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15771459">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal (GI) tract. They typically present as subepithelial neoplasms in the stomach and small intestine, but can involve any portion of the GI tract. GISTs occur predominantly in older adults and are less common in children and young adults. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Molecular alterations
         </strong>
         – Molecular alterations that are commonly identified in GISTs include mutations in
         <em>
          KIT
         </em>
         , platelet-derived growth factor receptor alpha (
         <em>
          PDGFRA)
         </em>
         , and the family of succinate dehydrogenase (
         <em>
          SDH
         </em>
         ) genes. Other molecular alterations are less common. An assessment of mutation status is advised during the initial evaluation of most patients diagnosed with GIST because clinical responses to systemic therapy (eg,
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         and other tyrosine kinase inhibitors [TKIs]) correlate with tumor genotype and influence treatment options. (See
         <a class="local">
          'Molecular alterations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Patients with GISTs can present with a wide range of symptoms based on age and location of the primary tumor. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above and
         <a class="local">
          'Location'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adult patients
         </strong>
         – Most adult patients with subepithelial masses are asymptomatic and their tumors are discovered incidentally. Others may present with nonspecific chronic symptoms (eg, early satiety or bloating). Some tumors may grow large enough to ulcerate, cause pain, or result in tumor rupture, GI bleeding, bowel perforation, or GI obstruction. (See
         <a class="local">
          'Adults'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pediatric and AYA patients
         </strong>
         – Pediatric and adolescent and young adult (AYA) patients commonly present with GI bleeding, fatigue, and anemia. (See
         <a class="local">
          'Pediatric and AYA patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
         – GISTs are detected either incidentally in asymptomatic patients, or during the evaluation of the symptomatic patient. (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Imaging and diagnostic procedures
         </strong>
         – Both imaging (eg, computed tomography [CT] of the abdomen and pelvis) and endoscopic procedures (eg, upper endoscopy with endoscopic ultrasound [EUS]) are necessary to the initial diagnostic evaluation of GIST. (See
         <a class="local">
          'Imaging the primary tumor'
         </a>
         above and
         <a class="local">
          'Diagnostic procedures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tissue sampling
         </strong>
         – Whenever possible, we perform preoperative biopsy rather than resection to confirm the diagnosis. (See
         <a class="local">
          'Tissue sampling'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of GIST is established using histopathology, immunohistochemistry (IHC)  (
         <a class="graphic graphic_table graphicRef79128" href="/z/d/graphic/79128.html" rel="external">
          table 1
         </a>
         ), and identification of disease-specific molecular alterations. (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Molecular alterations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <em>
           KIT
          </em>
         </strong>
         <strong>
          mutations
         </strong>
         – Approximately 95 percent of GISTs are positive for expression of the receptor tyrosine kinase KIT (CD117) by IHC. However, not every GIST with KIT expression carries a
         <em>
          KIT
         </em>
         mutation. (See
         <a class="local">
          'KIT mutations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <em>
           PDGFRA
          </em>
         </strong>
         <strong>
          mutations
         </strong>
         – Mutations in
         <em>
          PDGFRA
         </em>
         are mutually exclusive with
         <em>
          KIT
         </em>
         . Tumors with the
         <em>
          D842V
         </em>
         mutation in exon 18 of
         <em>
          PDGFRA
         </em>
         are characterized by relative insensitivity to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         and are treated using alternative agents such as
         <a class="drug drug_general" data-topicid="126556" href="/z/d/drug information/126556.html" rel="external">
          avapritinib
         </a>
         and
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          ripretinib
         </a>
         . (See
         <a class="local">
          'PDGFRA mutations'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7725.html" rel="external">
          "Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors", section on 'Avapritinib for PDGFRA D842V mutant tumors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7725.html" rel="external">
          "Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors", section on 'Ripretinib'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <em>
           KIT
          </em>
         </strong>
         <strong>
          and
         </strong>
         <strong>
          <em>
           PDGFRA
          </em>
         </strong>
         <strong>
          wild-type tumors
         </strong>
         –
         <em>
          KIT/PDGFRA
         </em>
         wild-type GISTs (eg, tumors without detectable mutations in
         <em>
          KIT
         </em>
         or
         <em>
          PDGFRA
         </em>
         ) may harbor epigenetic changes in succinate dehydrogenase C (SDHC), or mutations in
         <em>
          SDHx
         </em>
         , neurofibromatosis type 1 (
         <em>
          NF1
         </em>
         ), or
         <em>
          BRAF
         </em>
         V600E. (See
         <a class="local">
          'KIT/PDGFRA wild-type GISTs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation of metastatic disease
         </strong>
         – For all patients with a confirmed diagnosis of GIST, we evaluate for metastatic disease using CT and/or magnetic resonance imaging (MRI) of the abdomen and pelvis. Positron emission tomography (PET)-CT or MRI may be used to better visualize hepatic metastases; PET-CT may also be used to follow response to therapy. For primary tumors ≥2 cm in size, we also obtain either a chest radiograph or CT of the chest. (See
         <a class="local">
          'Evaluation for metastatic disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk stratification and prognosis
         </strong>
         – Various prognostic models and risk stratification schemes have been developed to predict the risks of metastatic disease, identify patients at risk for recurrence, and individualize management with systemic therapy using TKIs. Risk factors that have been incorporated into these models include tumor size, mitotic rate, primary site, and tumor rupture. (See
         <a class="local">
          'Risk stratification and prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The Armed Forces Institute of Pathology (AFIP) prognostic model  (
         <a class="graphic graphic_table graphicRef139776" href="/z/d/graphic/139776.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef60930" href="/z/d/graphic/60930.html" rel="external">
          table 4
         </a>
         ) is the most commonly used risk stratification scheme in the United States, although others are available. (See
         <a class="local">
          'Prognostic and risk stratification models'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1785542360">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges George Demetri, MD, and Jeffrey Morgan, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Rubin BP, Fletcher JA, Fletcher CD. Molecular Insights into the Histogenesis and Pathogenesis of Gastrointestinal Stromal Tumors. Int J Surg Pathol 2000; 8:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miettinen M, Lasota J. Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999; 30:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reith JD, Goldblum JR, Lyles RH, Weiss SW. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol 2000; 13:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004; 28:889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beltran MA, Cruces KS. Primary tumors of jejunum and ileum as a cause of intestinal obstruction: a case control study. Int J Surg 2007; 5:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Søreide K, Sandvik OM, Søreide JA, et al. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol 2016; 40:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma GL, Murphy JD, Martinez ME, Sicklick JK. Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer Epidemiol Biomarkers Prev 2015; 24:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cassier PA, Ducimetière F, Lurkin A, et al. A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region. Br J Cancer 2010; 103:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nilsson B, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden. Cancer 2005; 103:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tryggvason G, Gíslason HG, Magnússon MK, Jónasson JG. Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005; 117:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet 2013; 382:973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benesch M, Wardelmann E, Ferrari A, et al. Gastrointestinal stromal tumors (GIST) in children and adolescents: A comprehensive review of the current literature. Pediatr Blood Cancer 2009; 53:1171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boikos SA, Pappo AS, Killian JK, et al. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol 2016; 2:922.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012; 13:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 2005; 100:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez EA, Livingstone AS, Franceschi D, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 2006; 202:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel N, Benipal B. Incidence of Gastrointestinal Stromal Tumors in the United States from 2001-2015: A United States Cancer Statistics Analysis of 50 States. Cureus 2019; 11:e4120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawanowa K, Sakuma Y, Sakurai S, et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 2006; 37:1527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agaimy A, Wünsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007; 31:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janeway KA, Liegl B, Harlow A, et al. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res 2007; 67:9084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prakash S, Sarran L, Socci N, et al. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol 2005; 27:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ulanja MB, Rishi M, Beutler BD, et al. Racial Disparity in Incidence and Survival for Gastrointestinal Stromal Tumors (GISTs): an Analysis of SEER Database. J Racial Ethn Health Disparities 2019; 6:1035.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newman PL, Wadden C, Fletcher CD. Gastrointestinal stromal tumours: correlation of immunophenotype with clinicopathological features. J Pathol 1991; 164:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Besmer P, Murphy JE, George PC, et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 1986; 320:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61:8118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999; 154:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirota S, Nishida T, Isozaki K, et al. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol 2001; 193:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 2002; 10:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakurai S, Fukasawa T, Chong JM, et al. C-kit gene abnormalities in gastrointestinal stromal tumors (tumors of interstitial cells of Cajal. Jpn J Cancer Res 1999; 90:1321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang L, Vargas H, French SW. Cellular origin of gastrointestinal stromal tumors: a study of 27 cases. Arch Pathol Lab Med 2000; 124:1471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sircar K, Hewlett BR, Huizinga JD, et al. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 1999; 23:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000; 13:1134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamoto H, Oda Y, Kawaguchi K, et al. c-kit and PDGFRA mutations in extragastrointestinal stromal tumor (gastrointestinal stromal tumor of the soft tissue). Am J Surg Pathol 2004; 28:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miettinen M, Monihan JM, Sarlomo-Rikala M, et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol 1999; 23:1109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PC. The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol 2001; 54:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broudy VC. Stem cell factor and hematopoiesis. Blood 1997; 90:1345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Théou-Anton N, Tabone S, Brouty-Boyé D, et al. Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism. Br J Cancer 2006; 94:1180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23:5357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agaimy A, Märkl B, Arnholdt H, et al. Sporadic segmental Interstitial cell of cajal hyperplasia (microscopic GIST) with unusual diffuse longitudinal growth replacing the muscularis propria: differential diagnosis to hereditary GIST syndromes. Int J Clin Exp Pathol 2010; 3:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schaefer IM, Wang Y, Liang CW, et al. MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nat Commun 2017; 8:14674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Y, Marino-Enriquez A, Bennett RR, et al. Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat Genet 2014; 46:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 2006; 30:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mussi C, Schildhaus HU, Gronchi A, et al. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin Cancer Res 2008; 14:4550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maeyama H, Hidaka E, Ota H, et al. Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 2001; 120:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishida T, Hirota S, Taniguchi M, et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 1998; 19:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirota S, Okazaki T, Kitamura Y, et al. Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene. Am J Surg Pathol 2000; 24:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beghini A, Tibiletti MG, Roversi G, et al. Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 2001; 92:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirota S, Nishida T, Isozaki K, et al. Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. Gastroenterology 2002; 122:1493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chompret A, Kannengiesser C, Barrois M, et al. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology 2004; 126:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Raedt T, Cools J, Debiec-Rychter M, et al. Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA. Gastroenterology 2006; 131:1907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasini B, Matyakhina L, Bei T, et al. Multiple gastrointestinal stromal and other tumors caused by platelet-derived growth factor receptor alpha gene mutations: a case associated with a germline V561D defect. J Clin Endocrinol Metab 2007; 92:3728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ricci R, Martini M, Cenci T, et al. PDGFRA-mutant syndrome. Mod Pathol 2015; 28:954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersson J, Sihto H, Meis-Kindblom JM, et al. NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am J Surg Pathol 2005; 29:1170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pappo AS, Janeway KA. Pediatric gastrointestinal stromal tumors. Hematol Oncol Clin North Am 2009; 23:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stratakis CA, Carney JA. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J Intern Med 2009; 266:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gasparotto D, Rossi S, Campagna D, et al. Imatinib-Sensitizing KIT Mutation in a Carney-Stratakis-Associated GI Stromal Tumor. J Clin Oncol 2016; 34:e99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasini B, McWhinney SR, Bei T, et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 2008; 16:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McWhinney SR, Pasini B, Stratakis CA, International Carney Triad and Carney-Stratakis Syndrome Consortium. Familial gastrointestinal stromal tumors and germ-line mutations. N Engl J Med 2007; 357:1054.
          </a>
         </li>
         <li class="breakAll">
          Tischler AS, de Krijger RR, Gill A, et al. Familial paraganglioma-phaeochromocytoma syndromes caused by SDHB, SDHC, and SDHD mutations. In: WHO classification of Tumours of Endocrine Organs, 4th ed, Lloyd RV, Osamura RY, Kloppel G, Rosai J (Eds), IARC, Lyon 2017. p.262.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janeway KA, Kim SY, Lodish M, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A 2011; 108:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Mehren M, Joensuu H. Gastrointestinal Stromal Tumors. J Clin Oncol 2018; 36:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schaefer IM, Cote GM, Hornick JL. Contemporary Sarcoma Diagnosis, Genetics, and Genomics. J Clin Oncol 2018; 36:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc 1999; 74:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haller F, Moskalev EA, Faucz FR, et al. Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad. Endocr Relat Cancer 2014; 21:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matyakhina L, Bei TA, McWhinney SR, et al. Genetics of carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors. J Clin Endocrinol Metab 2007; 92:2938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Welander J, Söderkvist P, Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer 2011; 18:R253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boikos SA, Xekouki P, Fumagalli E, et al. Carney triad can be (rarely) associated with germline succinate dehydrogenase defects. Eur J Hum Genet 2016; 24:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emory TS, Sobin LH, Lukes L, et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999; 23:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liegl B, Hornick JL, Lazar AJ. Contemporary pathology of gastrointestinal stromal tumors. Hematol Oncol Clin North Am 2009; 23:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singhal S, Singhal A, Tugnait R, et al. Anorectal gastrointestinal stromal tumor: a case report and literature review. Case Rep Gastrointest Med 2013; 2013:934875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parab TM, DeRogatis MJ, Boaz AM, et al. Gastrointestinal stromal tumors: a comprehensive review. J Gastrointest Oncol 2019; 10:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hama Y, Okizuka H, Odajima K, et al. Gastrointestinal stromal tumor of the rectum. Eur Radiol 2001; 11:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gasparotto D, Rossi S, Bearzi I, et al. Multiple primary sporadic gastrointestinal stromal tumors in the adult: an underestimated entity. Clin Cancer Res 2008; 14:5715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mucciarini C, Rossi G, Bertolini F, et al. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer 2007; 7:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caterino S, Lorenzon L, Petrucciani N, et al. Gastrointestinal stromal tumors: correlation between symptoms at presentation, tumor location and prognostic factors in 47 consecutive patients. World J Surg Oncol 2011; 9:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bümming P, Ahlman H, Andersson J, et al. Population-based study of the diagnosis and treatment of gastrointestinal stromal tumours. Br J Surg 2006; 93:836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuval JB, Khalaileh A, Abu-Gazala M, et al. The true incidence of gastric GIST-a study based on morbidly obese patients undergoing sleeve gastrectomy. Obes Surg 2014; 24:2134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006; 30:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maynard MA, Marino-Enriquez A, Fletcher JA, et al. Thyroid hormone inactivation in gastrointestinal stromal tumors. N Engl J Med 2014; 370:1327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miettinen M, Lasota J, Sobin LH. Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol 2005; 29:1373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agaram NP, Laquaglia MP, Ustun B, et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res 2008; 14:3204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Call J, Walentas CD, Eickhoff JC, Scherzer N. Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry. BMC Cancer 2012; 12:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tateishi U, Hasegawa T, Satake M, Moriyama N. Gastrointestinal stromal tumor. Correlation of computed tomography findings with tumor grade and mortality. J Comput Assist Tomogr 2003; 27:792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scarpa M, Bertin M, Ruffolo C, et al. A systematic review on the clinical diagnosis of gastrointestinal stromal tumors. J Surg Oncol 2008; 98:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SJ, Lee SW. Performance of F-18 FDG PET/CT for predicting malignant potential of gastrointestinal stromal tumors: A systematic review and meta-analysis. J Gastroenterol Hepatol 2018; 33:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reddy RM, Fleshman JW. Colorectal gastrointestinal stromal tumors: a brief review. Clin Colon Rectal Surg 2006; 19:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy AD, Remotti HE, Thompson WM, et al. Anorectal gastrointestinal stromal tumors: CT and MR imaging features with clinical and pathologic correlation. AJR Am J Roentgenol 2003; 180:1607.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: GIST. https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on January 29, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watson RR, Binmoeller KF, Hamerski CM, et al. Yield and performance characteristics of endoscopic ultrasound-guided fine needle aspiration for diagnosing upper GI tract stromal tumors. Dig Dis Sci 2011; 56:1757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tio TL, Tytgat GN, den Hartog Jager FC. Endoscopic ultrasonography for the evaluation of smooth muscle tumors in the upper gastrointestinal tract: an experience with 42 cases. Gastrointest Endosc 1990; 36:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eriksson M, Reichardt P, Sundby Hall K, et al. Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence? Eur J Cancer 2016; 59:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janeway KA, Pappo A. Treatment guidelines for gastrointestinal stromal tumors in children and young adults. J Pediatr Hematol Oncol 2012; 34 Suppl 2:S69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamoto H, Tobo T, Nakamori M, et al. Neurofibromatosis type 1-related gastrointestinal stromal tumors: a special reference to loss of heterozygosity at 14q and 22q. J Cancer Res Clin Oncol 2009; 135:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flavahan WA, Drier Y, Johnstone SE, et al. Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs. Nature 2019; 575:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emile JF, Théou N, Tabone S, et al. Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol 2004; 2:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liegl B, Hornick JL, Corless CL, Fletcher CD. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol 2009; 33:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Novelli M, Rossi S, Rodriguez-Justo M, et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology 2010; 57:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol 2009; 33:1401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           West RB, Corless CL, Chen X, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 2004; 165:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duensing A, Joseph NE, Medeiros F, et al. Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res 2004; 64:5127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang GH, Srivastava A, Kim YE, et al. DOG1 and PKC-θ are useful in the diagnosis of KIT-negative gastrointestinal stromal tumors. Mod Pathol 2011; 24:866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chakravarty D, Johnson A, Sklar J, et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 2022; 40:1231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000; 156:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersson J, Sjögren H, Meis-Kindblom JM, et al. The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 2002; 160:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 2011; 11:865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lasota J, Corless CL, Heinrich MC, et al. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol 2008; 21:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martín J, Poveda A, Llombart-Bosch A, et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 2005; 23:6190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joensuu H, Rutkowski P, Nishida T, et al. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. J Clin Oncol 2015; 33:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lasota J, Dansonka-Mieszkowska A, Sobin LH, Miettinen M. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest 2004; 84:874.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szucs Z, Thway K, Fisher C, et al. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol 2017; 13:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gasparotto D, Rossi S, Polano M, et al. Quadruple-Negative GIST Is a Sentinel for Unrecognized Neurofibromatosis Type 1 Syndrome. Clin Cancer Res 2017; 23:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rege TA, Wagner AJ, Corless CL, et al. "Pediatric-type" gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behavior. Am J Surg Pathol 2011; 35:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agaram NP, Wong GC, Guo T, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 2008; 47:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hostein I, Faur N, Primois C, et al. BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol 2010; 133:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janku F, Wheler JJ, Naing A, et al. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget 2012; 3:1566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corless CL. Gastrointestinal stromal tumors: what do we know now? Mod Pathol 2014; 27 Suppl 1:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atiq MA, Davis JL, Hornick JL, et al. Mesenchymal tumors of the gastrointestinal tract with NTRK rearrangements: a clinicopathological, immunophenotypic, and molecular study of eight cases, emphasizing their distinction from gastrointestinal stromal tumor (GIST). Mod Pathol 2021; 34:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shi E, Chmielecki J, Tang CM, et al. FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. J Transl Med 2016; 14:339.
          </a>
         </li>
         <li class="breakAll">
          Atlas of Tumor Pathology: Tumors of the esophagus and stomach. Electronic fascicle v2.0b, Armed Forces Institute of Pathology, Washington DC.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandrasegaran K, Rajesh A, Rushing DA, et al. Gastrointestinal stromal tumors: CT and MRI findings. Eur Radiol 2005; 15:1407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007; 5 Suppl 2:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gayed I, Vu T, Iyer R, et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004; 45:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamiyama Y, Aihara R, Nakabayashi T, et al. 18F-fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg 2005; 29:1429.
          </a>
         </li>
         <li class="breakAll">
          DeMatteo RP, Maki RG, Agulnik M, et al. Gastrointestinal stromal tumor. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.523. Corrected at 4th printing, 2018.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang HY, Li CF, Huang WW, et al. A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome. Surgery 2007; 141:748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kukar M, Kapil A, Papenfuss W, et al. Gastrointestinal stromal tumors (GISTs) at uncommon locations: a large population based analysis. J Surg Oncol 2015; 111:696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hohenberger P, Ronellenfitsch U, Oladeji O, et al. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg 2010; 97:1854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hølmebakk T, Bjerkehagen B, Boye K, et al. Definition and clinical significance of tumour rupture in gastrointestinal stromal tumours of the small intestine. Br J Surg 2016; 103:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008; 39:1411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59:4297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chun HJ, Byun JY, Chun KA, et al. Gastrointestinal leiomyoma and leiomyosarcoma: CT differentiation. J Comput Assist Tomogr 1998; 22:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy AD, Remotti HE, Thompson WM, et al. Gastrointestinal stromal tumors: radiologic features with pathologic correlation. Radiographics 2003; 23:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghanem N, Altehoefer C, Furtwängler A, et al. Computed tomography in gastrointestinal stromal tumors. Eur Radiol 2003; 13:1669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burkill GJ, Badran M, Al-Muderis O, et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 2003; 226:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hatch GF 3rd, Wertheimer-Hatch L, Hatch KF, et al. Tumors of the esophagus. World J Surg 2000; 24:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Güller U, Tarantino I, Cerny T, et al. Population-based SEER trend analysis of overall and cancer-specific survival in 5138 patients with gastrointestinal stromal tumor. BMC Cancer 2015; 15:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002; 20:3898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim TW, Lee H, Kang YK, et al. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 2004; 10:3076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antonescu CR, Sommer G, Sarran L, et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003; 9:3329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wardelmann E, Losen I, Hans V, et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 2003; 106:887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bachet JB, Hostein I, Le Cesne A, et al. Prognosis and predictive value of KIT exon 11 deletion in GISTs. Br J Cancer 2009; 101:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wozniak A, Rutkowski P, Piskorz A, et al. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Ann Oncol 2012; 23:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wieczorek TJ, Faquin WC, Rubin BP, Cibas ES. Cytologic diagnosis of gastrointestinal stromal tumor with emphasis on the differential diagnosis with leiomyosarcoma. Cancer 2001; 93:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dematteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008; 112:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connolly EM, Gaffney E, Reynolds JV. Gastrointestinal stromal tumours. Br J Surg 2003; 90:1178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001; 8:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langer C, Gunawan B, Schüler P, et al. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg 2003; 90:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu PC, Langerman A, Ryan CW, et al. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery 2003; 134:656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Besana-Ciani I, Boni L, Dionigi G, et al. Outcome and long term results of surgical resection for gastrointestinal stromal tumors (GIST). Scand J Surg 2003; 92:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carboni F, Carlini M, Scardamaglia F, et al. Gastrointestinal stromal tumors of the stomach. A ten-year surgical experience. J Exp Clin Cancer Res 2003; 22:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gold JS, Gönen M, Gutiérrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009; 10:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bischof DA, Kim Y, Behman R, et al. A nomogram to predict disease-free survival after surgical resection of GIST. J Gastrointest Surg 2014; 18:2123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossi S, Miceli R, Messerini L, et al. Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol 2011; 35:1646.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7745 Version 52.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11493959" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Molecular Insights into the Histogenesis and Pathogenesis of Gastrointestinal Stromal Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11213830" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10534170" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Gastrointestinal stromal tumors: recent advances in understanding of their biology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10824931" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15223958" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17509501" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Primary tumors of jejunum and ileum as a cause of intestinal obstruction: a case control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26618334" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25277795" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20588273" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15648083" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15900576" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23623056" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Gastrointestinal stromal tumour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19499582" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Gastrointestinal stromal tumors (GIST) in children and adolescents: A comprehensive review of the current literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27011036" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22153892" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15654796" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16571433" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31037234" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Incidence of Gastrointestinal Stromal Tumors in the United States from 2001-2015: A United States Cancer Statistics Analysis of 50 States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16996566" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : High incidence of microscopic gastrointestinal stromal tumors in the stomach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17197927" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17909012" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15838387" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31215017" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Racial Disparity in Incidence and Survival for Gastrointestinal Stromal Tumors (GISTs): an Analysis of SEER Database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1649285" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Gastrointestinal stromal tumours: correlation of immunophenotype with clinicopathological features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9438854" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3007997" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11719439" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9916918" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11276010" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12075401" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Diagnosis of gastrointestinal stromal tumors: a consensus approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10665649" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : C-kit gene abnormalities in gastrointestinal stromal tumors (tumors of interstitial cells of Cajal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11035578" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Cellular origin of gastrointestinal stromal tumors: a study of 27 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10199467" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11048809" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15087667" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : c-kit and PDGFRA mutations in extragastrointestinal stromal tumor (gastrointestinal stromal tumor of the soft tissue).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10478672" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11215292" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The histopathological differential diagnosis of gastrointestinal stromal tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9269751" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Stem cell factor and hematopoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16570044" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15928335" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20606738" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Sporadic segmental Interstitial cell of cajal hyperplasia (microscopic GIST) with unusual diffuse longitudinal growth replacing the muscularis propria: differential diagnosis to hereditary GIST syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28270683" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24793134" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Dystrophin is a tumor suppressor in human cancers with myogenic programs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16330947" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18628470" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11208730" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9697690" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Familial gastrointestinal stromal tumours with germline mutation of the KIT gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10680913" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11505412" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11984533" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14699510" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17087943" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17566086" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Multiple gastrointestinal stromal and other tumors caused by platelet-derived growth factor receptor alpha gene mutations: a case associated with a germline V561D defect.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25975287" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : PDGFRA-mutant syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16096406" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19248968" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Pediatric gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19522824" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25547508" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Imatinib-Sensitizing KIT Mutation in a Carney-Stratakis-Associated GI Stromal Tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17667967" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17804857" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Familial gastrointestinal stromal tumors and germ-line mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17804857" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Familial gastrointestinal stromal tumors and germ-line mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21173220" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29220298" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Gastrointestinal Stromal Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29220288" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Contemporary Sarcoma Diagnosis, Genetics, and Genomics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10377927" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24859990" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17535989" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Genetics of carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22041710" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26173966" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Carney triad can be (rarely) associated with germline succinate dehydrogenase defects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10636102" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9888707" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19248970" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Contemporary pathology of gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23585972" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Anorectal gastrointestinal stromal tumor: a case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30788170" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Gastrointestinal stromal tumors: a comprehensive review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11218017" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Gastrointestinal stromal tumor of the rectum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18779314" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Multiple primary sporadic gastrointestinal stromal tumors in the adult: an underestimated entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18096058" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21284869" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Gastrointestinal stromal tumors: correlation between symptoms at presentation, tumor location and prognostic factors in 47 consecutive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16705644" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Population-based study of the diagnosis and treatment of gastrointestinal stromal tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24965544" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : The true incidence of gastric GIST-a study based on morbidly obese patients undergoing sleeve gastrectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15613856" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16625094" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24693892" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Thyroid hormone inactivation in gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16160481" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18483389" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Molecular characterization of pediatric gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22429770" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14501372" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Gastrointestinal stromal tumor. Correlation of computed tomography findings with tumor grade and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18668671" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : A systematic review on the clinical diagnosis of gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28994187" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Performance of F-18 FDG PET/CT for predicting malignant potential of gastrointestinal stromal tumors: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20011313" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Colorectal gastrointestinal stromal tumors: a brief review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12760929" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Anorectal gastrointestinal stromal tumors: CT and MR imaging features with clinical and pathologic correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12760929" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Anorectal gastrointestinal stromal tumors: CT and MR imaging features with clinical and pathologic correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21360279" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Yield and performance characteristics of endoscopic ultrasound-guided fine needle aspiration for diagnosing upper GI tract stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2210274" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Endoscopic ultrasonography for the evaluation of smooth muscle tumors in the upper gastrointestinal tract: an experience with 42 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27033260" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22525410" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Treatment guidelines for gastrointestinal stromal tumors in children and young adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19020900" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Neurofibromatosis type 1-related gastrointestinal stromal tumors: a special reference to loss of heterozygosity at 14q and 22q.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31666694" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12522257" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : PDGFRA activating mutations in gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12949711" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15224284" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19011564" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20716168" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19606013" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15215166" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15289315" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21358619" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : DOG1 and PKC-θare useful in the diagnosis of KIT-negative gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12094370" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Diagnosis of gastrointestinal stromal tumors: A consensus approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35175857" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10702394" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11786393" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22089421" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Gastrointestinal stromal tumours: origin and molecular oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18246046" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16135486" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25605837" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15146165" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27600498" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27390349" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Quadruple-Negative GIST Is a Sentinel for Unrecognized Neurofibromatosis Type 1 Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21358303" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : "Pediatric-type" gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behavior.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18615679" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20023270" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : BRAF mutation status in gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23248156" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : PIK3CA mutations in advanced cancers: characteristics and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24384849" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Gastrointestinal stromal tumors: what do we know now?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32669612" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Mesenchymal tumors of the gastrointestinal tract with NTRK rearrangements: a clinicopathological, immunophenotypic, and molecular study of eight cases, emphasizing their distinction from gastrointestinal stromal tumor (GIST).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27974047" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27974047" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15761716" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Gastrointestinal stromal tumors: CT and MRI findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17624289" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14734662" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16222452" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : 18F-fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16222452" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : 18F-fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17193820" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Gastrointestinal stromal tumors: pathology and prognosis at different sites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17560251" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25560251" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Gastrointestinal stromal tumors (GISTs) at uncommon locations: a large population based analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20730857" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26988241" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Definition and clinical significance of tumour rupture in gastrointestinal stromal tumours of the small intestine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18774375" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Risk stratification of patients diagnosed with gastrointestinal stromal tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10485475" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9448764" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Gastrointestinal leiomyoma and leiomyosarcoma: CT differentiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12640147" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Gastrointestinal stromal tumors: radiologic features with pathologic correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12835984" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Computed tomography in gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12563150" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10706912" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Tumors of the esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26223313" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Population-based SEER trend analysis of overall and cancer-specific survival in 5138 patients with gastrointestinal stromal tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12228211" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15131046" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12960119" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12918066" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19536093" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Prognosis and predictive value of KIT exon 11 deletion in GISTs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21527588" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11507702" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Cytologic diagnosis of gastrointestinal stromal tumor with emphasis on the differential diagnosis with leiomyosarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18076015" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14515284" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Gastrointestinal stromal tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11206225" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12594669" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14605627" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14582540" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Outcome and long term results of surgical resection for gastrointestinal stromal tumors (GIST).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14582694" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Gastrointestinal stromal tumors of the stomach. A ten-year surgical experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19793678" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25245766" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : A nomogram to predict disease-free survival after surgical resection of GIST.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21997685" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
